Table 2: Updated MIPS Benchmark Results Using DY2016 and PY2018 Logic,,,,,,,,,,,,,
,,,,,,,,,,,,,
Measure_Name,Measure_ID,Submission_Method,Measure_Type,Benchmark,Decile_3,Decile_4,Decile_5,Decile_6,Decile_7,Decile_8,Decile_9,Decile_10,TOPPED_OUT
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,EHR,Intermediate Outcome,Y,77.14 - 60.79,60.78 - 48.49,48.48 - 38.90,38.89 - 31.60,31.59 - 25.88,25.87 - 20.56,20.55 - 14.72,<= 14.71,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Claims,Intermediate Outcome,Y,44.44 - 29.04,29.03 - 19.52,19.51 - 14.72,14.71 - 11.12,11.11 - 8.34,8.33 - 5.57,5.56 - 2.79,<= 2.78,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,cmsWebInterface,Intermediate Outcome,Y,100 - 70,70 - 60,60 - 50,50 - 40,40 - 30,30 - 20,20 - 10,<= 10,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Registry/QCDR,Intermediate Outcome,Y,68.31 - 50.63,50.62 - 37.51,37.50 - 28.70,28.69 - 20.01,20.00 - 13.60,13.59 - 9.03,9.02 - 2.71,<= 2.70,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,EHR,Process,Y,74.19 - 78.56,78.57 - 82.13,82.14 - 85.18,85.19 - 87.92,87.93 - 90.90,90.91 - 93.74,93.75 - 97.72,>= 97.73,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,Registry/QCDR,Process,Y,93.33 - 96.96,96.97 - 98.40,98.41 - 99.99,--,--,--,--,100,Yes
Coronary Artery Disease (CAD): Antiplatelet Therapy,6,Registry/QCDR,Process,Y,84.13 - 87.99,88.00 - 90.66,90.67 - 92.85,92.86 - 95.09,95.10 - 97.08,97.09 - 99.99,--,100,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,EHR,Process,Y,76.74 - 80.30,80.31 - 83.17,83.18 - 85.28,85.29 - 87.15,87.16 - 89.73,89.74 - 91.91,91.92 - 94.86,>= 94.87,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,Registry/QCDR,Process,Y,96.17 - 98.11,98.12 - 99.76,99.77 - 99.99,--,--,--,--,100,Yes
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,EHR,Process,Y,80.49 - 85.61,85.62 - 88.97,88.98 - 91.29,91.30 - 93.04,93.05 - 94.73,94.74 - 96.34,96.35 - 99.99,100,No
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,Registry/QCDR,Process,Y,95.45 - 98.05,98.06 - 99.28,99.29 - 99.99,--,--,--,--,100,Yes
Anti-Depressant Medication Management,9,EHR,Process,Y,16.67 - 31.06,31.07 - 42.18,42.19 - 53.15,53.16 - 71.73,71.74 - 82.78,82.79 - 88.88,88.89 - 94.43,>= 94.44,No
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,EHR,Process,Y,79.11 - 86.57,86.58 - 90.61,90.62 - 93.87,93.88 - 96.31,96.32 - 98.01,98.02 - 99.10,99.11 - 99.99,100,No
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,12,Registry/QCDR,Process,Y,96.47 - 99.16,99.17 - 99.99,--,--,--,--,--,100,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,14,Registry/QCDR,Process,Y,76.54 - 89.80,89.81 - 96.53,96.54 - 99.70,99.71 - 99.99,--,--,--,100,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,EHR,Process,Y,33.90 - 47.61,47.62 - 57.88,57.89 - 67.02,67.03 - 75.36,75.37 - 82.48,82.49 - 90.02,90.03 - 95.99,>= 96.00,No
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,19,Registry/QCDR,Process,Y,70.29 - 84.41,84.42 - 92.72,92.73 - 98.56,98.57 - 99.99,--,--,--,100,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Claims,Process,Y,99.17 - 99.99,--,--,--,--,--,--,100,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin,21,Registry/QCDR,Process,Y,98.67 - 99.99,--,--,--,--,--,--,100,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),23,Registry/QCDR,Process,Y,98.68 - 99.99,--,--,--,--,--,--,100,Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Claims,Process,Y,32.35 - 63.63,63.64 - 92.30,92.31 - 96.20,96.21 - 97.61,97.62 - 99.99,--,--,100,Yes
Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older,24,Registry/QCDR,Process,Y,26.32 - 45.09,45.10 - 55.31,55.32 - 60.20,60.21 - 69.99,70.00 - 80.55,80.56 - 99.99,--,100,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Claims,Process,Y,32.79 - 42.36,42.37 - 49.00,49.01 - 55.90,55.91 - 62.54,62.55 - 70.68,70.69 - 82.88,82.89 - 95.49,>= 95.50,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,39,Registry/QCDR,Process,Y,11.38 - 22.43,22.44 - 34.71,34.72 - 45.25,45.26 - 58.10,58.11 - 67.97,67.98 - 78.45,78.46 - 88.23,>= 88.24,No
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,44,Registry/QCDR,Process,Y,90.35 - 95.89,95.90 - 97.38,97.39 - 99.99,--,--,--,--,100,Yes
Medication Reconciliation Post-Discharge,46,Claims,Process,Y,95.74 - 98.40,98.41 - 99.99,--,--,--,--,--,100,Yes
Medication Reconciliation Post-Discharge,46,Registry/QCDR,Process,Y,94.24 - 97.62,97.63 - 99.92,99.93 - 99.99,--,--,--,--,100,Yes
Care Plan,47,Claims,Process,Y,50.32 - 82.60,82.61 - 92.88,92.89 - 97.45,97.46 - 99.30,99.31 - 99.99,--,--,100,Yes
Care Plan,47,Registry/QCDR,Process,Y,24.33 - 45.01,45.02 - 65.74,65.75 - 82.16,82.17 - 91.89,91.90 - 97.31,97.32 - 99.71,99.72 - 99.99,100,No
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Claims,Process,Y,3.88 - 13.85,13.86 - 72.40,72.41 - 96.68,96.69 - 99.99,--,--,--,100,Yes
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,48,Registry/QCDR,Process,Y,12.22 - 31.74,31.75 - 52.36,52.37 - 70.44,70.45 - 84.26,84.27 - 95.10,95.11 - 99.50,99.51 - 99.99,100,No
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Claims,Process,Y,97.30 - 98.87,98.88 - 99.99,--,--,--,--,--,100,Yes
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,50,Registry/QCDR,Process,Y,47.22 - 59.99,60.00 - 68.98,68.99 - 75.63,75.64 - 85.49,85.50 - 92.58,92.59 - 99.65,99.66 - 99.99,100,No
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Claims,Process,Y,38.10 - 77.26,77.27 - 92.44,92.45 - 98.75,98.76 - 99.99,--,--,--,100,Yes
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,51,Registry/QCDR,Process,Y,25.00 - 45.44,45.45 - 60.42,60.43 - 75.75,75.76 - 86.45,86.46 - 93.82,93.83 - 99.35,99.36 - 99.99,100,No
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Claims,Process,Y,90.14 - 98.14,98.15 - 99.99,--,--,--,--,--,100,Yes
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,52,Registry/QCDR,Process,Y,90.16 - 95.21,95.22 - 96.48,96.49 - 98.85,98.86 - 99.99,--,--,--,100,Yes
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,EHR,Process,Y,80.95 - 88.36,88.37 - 91.76,91.77 - 93.87,93.88 - 95.60,95.61 - 96.87,96.88 - 98.21,98.22 - 99.99,100,No
Appropriate Treatment for Children with Upper Respiratory Infection (URI),65,Registry/QCDR,Process,Y,91.49 - 95.01,95.02 - 97.02,97.03 - 97.84,97.85 - 98.69,98.70 - 99.19,99.20 - 99.74,99.75 - 99.99,100,Yes
Appropriate Testing for Children with Pharyngitis,66,EHR,Process,Y,36.71 - 60.04,60.05 - 72.40,72.41 - 78.37,78.38 - 83.32,83.33 - 87.62,87.63 - 91.42,91.43 - 94.58,>= 94.59,No
Appropriate Testing for Children with Pharyngitis,66,Registry/QCDR,Process,Y,64.57 - 69.60,69.61 - 75.41,75.42 - 81.74,81.75 - 85.50,85.51 - 87.95,87.96 - 91.77,91.78 - 97.54,>= 97.55,No
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow,67,Registry/QCDR,Process,Y,8.00 - 12.49,12.50 - 22.72,22.73 - 28.52,28.53 - 34.61,34.62 - 78.78,78.79 - 99.99,--,100,No
Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy,68,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hematology: Multiple Myeloma: Treatment with Bisphosphonates,69,Registry/QCDR,Process,Y,42.86 - 47.49,47.50 - 64.51,64.52 - 66.66,66.67 - 71.42,71.43 - 71.87,71.88 - 76.91,76.92 - 92.30,>= 92.31,No
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry,70,Registry/QCDR,Process,Y,16.67 - 23.20,23.21 - 32.25,32.26 - 35.94,35.95 - 67.85,67.86 - 95.44,95.45 - 99.99,--,100,No
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Claims,Process,Y,95.24 - 98.60,98.61 - 99.99,--,--,--,--,--,100,Yes
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,76,Registry/QCDR,Process,Y,95.67 - 99.08,99.09 - 99.99,--,--,--,--,--,100,Yes
Acute Otitis Externa (AOE): Topical Therapy,91,Claims,Process,Y,43.36 - 86.60,86.61 - 93.21,93.22 - 99.65,99.66 - 99.99,--,--,--,100,Yes
Acute Otitis Externa (AOE): Topical Therapy,91,Registry/QCDR,Process,Y,67.34 - 78.76,78.77 - 86.33,86.34 - 91.32,91.33 - 95.23,95.24 - 97.36,97.37 - 99.99,--,100,No
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Claims,Process,Y,89.12 - 93.50,93.51 - 96.35,96.36 - 97.82,97.83 - 99.92,99.93 - 99.99,--,--,100,Yes
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,93,Registry/QCDR,Process,Y,63.16 - 77.35,77.36 - 83.96,83.97 - 89.65,89.66 - 93.32,93.33 - 96.14,96.15 - 99.99,--,100,No
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,EHR,Process,Y,59.34 - 75.73,75.74 - 83.90,83.91 - 91.99,92.00 - 98.30,98.31 - 99.99,--,--,100,No
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer,104,Registry/QCDR,Process,Y,39.65 - 48.16,48.17 - 55.05,55.06 - 76.22,76.23 - 93.25,93.26 - 99.59,99.60 - 99.99,--,100,No
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,EHR,Process,Y,1.51 - 3.56,3.57 - 8.10,8.11 - 17.48,17.49 - 30.28,30.29 - 54.72,54.73 - 77.56,77.57 - 96.66,>= 96.67,No
Osteoarthritis (OA): Function and Pain Assessment,109,Claims,Process,Y,87.28 - 95.71,95.72 - 98.71,98.72 - 99.88,99.89 - 99.99,--,--,--,100,Yes
Osteoarthritis (OA): Function and Pain Assessment,109,Registry/QCDR,Process,Y,34.62 - 63.00,63.01 - 86.63,86.64 - 94.37,94.38 - 99.99,--,--,--,100,No
Preventive Care and Screening: Influenza Immunization,110,EHR,Process,Y,15.50 - 23.63,23.64 - 31.20,31.21 - 38.65,38.66 - 46.76,46.77 - 56.01,56.02 - 67.49,67.50 - 84.98,>= 84.99,No
Preventive Care and Screening: Influenza Immunization,110,Claims,Process,Y,29.52 - 41.41,41.42 - 56.31,56.32 - 71.18,71.19 - 82.88,82.89 - 94.14,94.15 - 99.41,99.42 - 99.99,100,No
Preventive Care and Screening: Influenza Immunization,110,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Preventive Care and Screening: Influenza Immunization,110,Registry/QCDR,Process,Y,29.85 - 41.42,41.43 - 53.84,53.85 - 66.02,66.03 - 76.93,76.94 - 87.80,87.81 - 96.40,96.41 - 99.99,100,No
Pneumococcal Vaccination Status for Older Adults,111,EHR,Process,Y,19.01 - 31.06,31.07 - 42.70,42.71 - 53.43,53.44 - 62.85,62.86 - 71.81,71.82 - 80.42,80.43 - 90.40,>= 90.41,No
Pneumococcal Vaccination Status for Older Adults,111,Claims,Process,Y,49.76 - 61.10,61.11 - 70.10,70.11 - 77.31,77.32 - 82.95,82.96 - 89.43,89.44 - 95.66,95.67 - 99.99,100,No
Pneumococcal Vaccination Status for Older Adults,111,Registry/QCDR,Process,Y,30.23 - 44.52,44.53 - 55.55,55.56 - 63.63,63.64 - 70.42,70.43 - 76.37,76.38 - 83.76,83.77 - 95.44,>= 95.45,No
Breast Cancer Screening,112,EHR,Process,Y,22.28 - 32.74,32.75 - 42.31,42.32 - 51.05,51.06 - 58.43,58.44 - 65.67,65.68 - 73.43,73.44 - 82.30,>= 82.31,No
Breast Cancer Screening,112,Claims,Process,Y,44.44 - 52.07,52.08 - 58.44,58.45 - 64.28,64.29 - 70.96,70.97 - 79.84,79.85 - 90.23,90.24 - 99.99,100,No
Breast Cancer Screening,112,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Breast Cancer Screening,112,Registry/QCDR,Process,Y,35.99 - 48.25,48.26 - 57.57,57.58 - 67.38,67.39 - 75.24,75.25 - 85.30,85.31 - 93.44,93.45 - 99.99,100,No
Colorectal Cancer Screening,113,EHR,Process,Y,13.49 - 24.00,24.01 - 33.96,33.97 - 44.38,44.39 - 54.79,54.80 - 64.00,64.01 - 73.37,73.38 - 83.50,>= 83.51,No
Colorectal Cancer Screening,113,Claims,Process,Y,36.60 - 50.99,51.00 - 62.49,62.50 - 71.22,71.23 - 79.99,80.00 - 88.63,88.64 - 97.72,97.73 - 99.99,100,No
Colorectal Cancer Screening,113,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Colorectal Cancer Screening,113,Registry/QCDR,Process,Y,35.90 - 49.50,49.51 - 60.82,60.83 - 70.87,70.88 - 80.61,80.62 - 90.40,90.41 - 96.97,96.98 - 99.99,100,No
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis,116,Registry/QCDR,Process,Y,44.27 - 57.07,57.08 - 72.02,72.03 - 83.77,83.78 - 90.98,90.99 - 95.56,95.57 - 97.54,97.55 - 99.99,100,No
Diabetes: Eye Exam,117,EHR,Process,Y,20.61 - 31.99,32.00 - 45.52,45.53 - 66.01,66.02 - 89.11,89.12 - 95.64,95.65 - 98.25,98.26 - 99.72,>= 99.73,No
Diabetes: Eye Exam,117,Claims,Process,Y,72.00 - 96.87,96.88 - 99.99,--,--,--,--,--,100,Yes
Diabetes: Eye Exam,117,Registry/QCDR,Process,Y,77.26 - 89.99,90.00 - 95.81,95.82 - 98.48,98.49 - 99.99,--,--,--,100,Yes
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%),118,Registry/QCDR,Process,Y,76.00 - 78.56,78.57 - 81.07,81.08 - 83.90,83.91 - 86.35,86.36 - 88.72,88.73 - 92.25,92.26 - 98.17,>= 98.18,No
Diabetes: Medical Attention for Nephropathy,119,EHR,Process,Y,67.86 - 74.79,74.80 - 79.99,80.00 - 84.13,84.14 - 87.73,87.74 - 91.10,91.11 - 94.62,94.63 - 98.38,>= 98.39,No
Diabetes: Medical Attention for Nephropathy,119,Registry/QCDR,Process,Y,74.38 - 82.85,82.86 - 87.70,87.71 - 91.93,91.94 - 97.23,97.24 - 99.99,--,--,100,No
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,Registry/QCDR,Process,Y,66.15 - 85.22,85.23 - 96.42,96.43 - 99.99,--,--,--,--,100,Yes
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,Registry/QCDR,Process,Y,70.59 - 92.85,92.86 - 99.45,99.46 - 99.99,--,--,--,--,100,Yes
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,EHR,Process,Y,21.15 - 24.58,24.59 - 28.51,28.52 - 34.20,34.21 - 43.84,43.85 - 60.30,60.31 - 78.24,78.25 - 93.28,>= 93.29,No
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Claims,Process,Y,37.52 - 47.77,47.78 - 74.47,74.48 - 95.19,95.20 - 99.26,99.27 - 99.99,--,--,100,Yes
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Registry/QCDR,Process,Y,34.35 - 54.25,54.26 - 74.56,74.57 - 90.59,90.60 - 97.55,97.56 - 99.86,99.87 - 99.99,--,100,No
Documentation of Current Medications in the Medical Record,130,EHR,Process,Y,87.55 - 93.48,93.49 - 96.28,96.29 - 97.98,97.99 - 98.99,99.00 - 99.57,99.58 - 99.88,99.89 - 99.99,100,Yes
Documentation of Current Medications in the Medical Record,130,Claims,Process,Y,97.95 - 99.51,99.52 - 99.91,99.92 - 99.99,--,--,--,--,100,Yes
Documentation of Current Medications in the Medical Record,130,Registry/QCDR,Process,Y,68.06 - 90.27,90.28 - 97.23,97.24 - 99.50,99.51 - 99.99,--,--,--,100,Yes
Pain Assessment and Follow-Up,131,Claims,Process,Y,80.57 - 96.91,96.92 - 99.63,99.64 - 99.99,--,--,--,--,100,Yes
Pain Assessment and Follow-Up,131,Registry/QCDR,Process,Y,15.80 - 39.99,40.00 - 62.78,62.79 - 84.05,84.06 - 95.25,95.26 - 99.54,99.55 - 99.99,--,100,No
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,EHR,Process,Y,4.88 - 10.17,10.18 - 17.59,17.60 - 28.28,28.29 - 42.29,42.30 - 56.82,56.83 - 73.29,73.30 - 87.49,>= 87.50,No
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Claims,Process,Y,12.94 - 53.91,53.92 - 80.22,80.23 - 96.98,96.99 - 99.99,--,--,--,100,Yes
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,cmsWebInterface,Process,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Registry/QCDR,Process,Y,17.11 - 45.64,45.65 - 73.81,73.82 - 90.05,90.06 - 98.49,98.50 - 99.99,--,--,100,No
Melanoma: Continuity of Care - Recall System,137,Registry/QCDR,Structure,Y,83.83 - 94.33,94.34 - 98.79,98.80 - 99.99,--,--,--,--,100,No
Melanoma: Coordination of Care,138,Registry/QCDR,Process,Y,49.44 - 63.63,63.64 - 78.25,78.26 - 92.58,92.59 - 99.99,--,--,--,100,No
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Claims,Outcome,Y,--,--,--,--,--,--,--,100,Yes
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Registry/QCDR,Outcome,Y,73.85 - 87.49,87.50 - 96.29,96.30 - 99.30,99.31 - 99.99,--,--,--,100,No
Oncology: Medical and Radiation - Pain Intensity Quantified,143,EHR,Process,Y,77.21 - 87.78,87.79 - 94.91,94.92 - 97.26,97.27 - 98.34,98.35 - 99.45,99.46 - 99.99,--,100,Yes
Oncology: Medical and Radiation - Pain Intensity Quantified,143,Registry/QCDR,Process,Y,90.31 - 95.39,95.40 - 97.12,97.13 - 98.56,98.57 - 99.25,99.26 - 99.99,--,--,100,Yes
Oncology: Medical and Radiation - Plan of Care for Pain,144,Registry/QCDR,Process,Y,48.64 - 80.38,80.39 - 89.88,89.89 - 94.33,94.34 - 98.43,98.44 - 99.99,--,--,100,No
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy,145,Claims,Process,Y,66.41 - 82.92,82.93 - 90.90,90.91 - 95.17,95.18 - 97.39,97.40 - 99.06,99.07 - 99.99,--,100,Yes
Radiology: Exposure Dose or Time Reported for Procedures Using Fluoroscopy,145,Registry/QCDR,Process,Y,73.10 - 88.03,88.04 - 94.91,94.92 - 98.15,98.16 - 99.53,99.54 - 99.99,--,--,100,Yes
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Claims,Process,Y,0.23 - 0.01,--,--,--,--,--,--,0,Yes
"Radiology: Inappropriate Use of ""Probably Benign"" Assessment Category in Screening Mammograms",146,Registry/QCDR,Process,Y,0.24 - 0.12,0.11 - 0.05,0.04 - 0.01,--,--,--,--,0,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Claims,Process,Y,76.47 - 87.17,87.18 - 94.05,94.06 - 97.00,97.01 - 99.99,--,--,--,100,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Registry/QCDR,Process,Y,93.04 - 97.96,97.97 - 99.99,--,--,--,--,--,100,Yes
Falls: Risk Assessment,154,Claims,Process,Y,96.95 - 99.99,--,--,--,--,--,--,100,Yes
Falls: Risk Assessment,154,Registry/QCDR,Process,Y,28.63 - 60.81,60.82 - 84.99,85.00 - 95.96,95.97 - 99.73,99.74 - 99.99,--,--,100,Yes
Falls: Plan of Care,155,Claims,Process,Y,55.81 - 84.61,84.62 - 99.20,99.21 - 99.99,--,--,--,--,100,Yes
Falls: Plan of Care,155,Registry/QCDR,Process,Y,67.86 - 86.78,86.79 - 94.99,95.00 - 98.21,98.22 - 99.99,--,--,--,100,Yes
HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis,160,EHR,Process,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,164,Registry/QCDR,Outcome,Y,11.40 - 9.10,9.09 - 7.70,7.69 - 6.81,6.80 - 5.56,5.55 - 4.29,4.28 - 3.09,3.08 - 1.55,<= 1.54,No
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate,165,Registry/QCDR,Outcome,Y,0.84 - 0.01,--,--,--,--,--,--,0,Yes
Coronary Artery Bypass Graft (CABG): Stroke,166,Registry/QCDR,Outcome,Y,2.38 - 1.80,1.79 - 1.27,1.26 - 0.72,0.71 - 0.01,--,--,--,0,Yes
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure,167,Registry/QCDR,Outcome,Y,3.51 - 2.71,2.70 - 2.16,2.15 - 1.86,1.85 - 1.29,1.28 - 0.89,0.88 - 0.01,--,0,Yes
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration,168,Registry/QCDR,Outcome,Y,3.95 - 3.14,3.13 - 2.64,2.63 - 1.80,1.79 - 1.28,1.27 - 0.88,0.87 - 0.01,--,0,Yes
Rheumatoid Arthritis (RA): Tuberculosis Screening,176,Registry/QCDR,Process,Y,32.00 - 48.14,48.15 - 55.55,55.56 - 68.00,68.01 - 80.42,80.43 - 99.03,99.04 - 99.99,--,100,No
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,Registry/QCDR,Process,Y,57.23 - 74.99,75.00 - 88.23,88.24 - 96.01,96.02 - 99.99,--,--,--,100,Yes
Rheumatoid Arthritis (RA): Functional Status Assessment,178,Registry/QCDR,Process,Y,67.61 - 81.39,81.40 - 90.58,90.59 - 95.94,95.95 - 99.99,--,--,--,100,Yes
Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis,179,Registry/QCDR,Process,Y,44.53 - 67.88,67.89 - 85.30,85.31 - 95.21,95.22 - 99.99,--,--,--,100,Yes
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,Registry/QCDR,Process,Y,52.68 - 75.78,75.79 - 87.95,87.96 - 95.05,95.06 - 99.57,99.58 - 99.99,--,--,100,Yes
Elder Maltreatment Screen and Follow-Up Plan,181,Claims,Process,Y,55.38 - 97.31,97.32 - 99.55,99.56 - 99.99,--,--,--,--,100,Yes
Elder Maltreatment Screen and Follow-Up Plan,181,Registry/QCDR,Process,Y,50.65 - 66.03,66.04 - 77.77,77.78 - 89.28,89.29 - 96.78,96.79 - 99.99,--,--,100,No
Functional Outcome Assessment,182,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Functional Outcome Assessment,182,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps

- Avoidance of Inappropriate Use",185,Claims,Process,Y,98.57 - 99.99,--,--,--,--,--,--,100,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps

- Avoidance of Inappropriate Use",185,Registry/QCDR,Process,Y,61.64 - 84.99,85.00 - 90.53,90.54 - 95.41,95.42 - 98.40,98.41 - 99.99,--,--,100,Yes
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,Registry/QCDR,Process,Y,88.89 - 96.48,96.49 - 99.99,--,--,--,--,--,100,Yes
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,EHR,Outcome,Y,85.25 - 90.62,90.63 - 93.40,93.41 - 95.58,95.59 - 96.87,96.88 - 97.82,97.83 - 98.77,98.78 - 99.99,100,No
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,Registry/QCDR,Outcome,Y,94.37 - 96.87,96.88 - 98.97,98.98 - 99.99,--,--,--,--,100,Yes
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,EHR,Outcome,Y,--,--,--,--,--,--,--,0,Yes
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Claims,Process,Y,91.72 - 96.22,96.23 - 98.17,98.18 - 99.99,--,--,--,--,100,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Registry/QCDR,Process,Y,97.81 - 99.84,99.85 - 99.99,--,--,--,--,--,100,Yes
"HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis",205,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Knee Impairments,217,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Hip Impairments,218,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Foot or Ankle Impairments,219,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Lumbar Impairments,220,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Shoulder Impairments,221,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"Functional Status Change for Patients with Elbow, Wrist or Hand Impairments",222,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Functional Status Change for Patients with Other General Orthopaedic Impairments,223,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Radiology: Reminder System for Screening Mammograms,225,Claims,Structure,Y,99.36 - 99.99,--,--,--,--,--,--,100,Yes
Radiology: Reminder System for Screening Mammograms,225,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100,Yes
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Claims,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,cmsWebInterface,Process,Y,0 - 55.22,55.22 - 61.76,61.76 - 68.18,68.18 - 73.85,73.85 - 79.55,79.55 - 85.67,85.67 - 92.31,>= 92.31,No
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,EHR,Process,N,--,--,--,--,--,--,--,--,--
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Controlling High Blood Pressure,236,EHR,Intermediate Outcome,Y,51.46 - 56.82,56.83 - 60.94,60.95 - 64.67,64.68 - 68.17,68.18 - 72.00,72.01 - 76.25,76.26 - 82.20,>= 82.21,No
Controlling High Blood Pressure,236,Claims,Intermediate Outcome,Y,58.57 - 63.97,63.98 - 68.82,68.83 - 73.90,73.91 - 78.56,78.57 - 83.32,83.33 - 88.31,88.32 - 94.88,>= 94.89,No
Controlling High Blood Pressure,236,cmsWebInterface,Intermediate Outcome,Y,0 - 30,30 - 40,40 - 50,50 - 60,60 - 70,70 - 80,80 - 90,>= 90,No
Controlling High Blood Pressure,236,Registry/QCDR,Intermediate Outcome,Y,52.41 - 60.04,60.05 - 65.67,65.68 - 70.61,70.62 - 76.82,76.83 - 84.61,84.62 - 93.39,93.40 - 99.99,100,No
Use of High-Risk Medications in the Elderly,238,EHR,Process,Y,8.04 - 4.75,4.74 - 2.68,2.67 - 1.32,1.31 - 0.54,0.53 - 0.05,0.04 - 0.01,--,0,Yes
Use of High-Risk Medications in the Elderly,238,Registry/QCDR,Process,Y,0.68 - 0.29,0.28 - 0.14,0.13 - 0.01,--,--,--,--,0,Yes
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,EHR,Process,Y,26.23 - 29.51,29.52 - 31.47,31.48 - 32.79,32.80 - 33.85,33.86 - 38.72,38.73 - 47.76,47.77 - 65.52,>= 65.53,No
Childhood Immunization Status,240,EHR,Process,Y,9.30 - 14.80,14.81 - 20.49,20.50 - 26.67,26.68 - 30.66,30.67 - 37.22,37.23 - 42.41,42.42 - 50.88,>= 50.89,No
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,Registry/QCDR,Process,Y,8.11 - 11.87,11.88 - 14.62,14.63 - 17.22,17.23 - 20.77,20.78 - 24.31,24.32 - 30.68,30.69 - 44.43,>= 44.44,No
Barrett's Esophagus,249,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Barrett's Esophagus,249,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Radical Prostatectomy Pathology Reporting,250,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Radical Prostatectomy Pathology Reporting,250,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Registry/QCDR,Process,Y,74.42 - 80.94,80.95 - 85.36,85.37 - 88.88,88.89 - 91.99,92.00 - 95.23,95.24 - 97.66,97.67 - 99.99,100,No
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Claims,Process,N,--,--,--,--,--,--,--,--,--
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Claims,Process,N,--,--,--,--,--,--,--,--,--
Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure,255,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7),258,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative Day #2),259,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Claims,Process,N,--,--,--,--,--,--,--,--,--
Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness,261,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Image Confirmation of Successful Excision of Image-Localized Breast Lesion,262,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Sentinel Lymph Node Biopsy for Invasive Breast Cancer,264,Registry/QCDR,Process,Y,97.96 - 99.21,99.22 - 99.99,--,--,--,--,--,100,Yes
Biopsy Follow-Up,265,Registry/QCDR,Process,Y,61.23 - 83.62,83.63 - 95.64,95.65 - 99.37,99.38 - 99.99,--,--,--,100,Yes
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Registry/QCDR,Process,Y,32.00 - 45.34,45.35 - 57.13,57.14 - 78.56,78.57 - 95.99,96.00 - 99.06,99.07 - 99.99,--,100,No
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Claims,Process,N,--,--,--,--,--,--,--,--,--
Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment,271,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy,275,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,Registry/QCDR,Process,Y,69.01 - 81.02,81.03 - 90.62,90.63 - 99.70,99.71 - 99.99,--,--,--,100,Yes
Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy,279,Registry/QCDR,Process,Y,90.08 - 96.26,96.27 - 99.16,99.17 - 99.99,--,--,--,--,100,Yes
Dementia: Cognitive Assessment,281,EHR,Process,Y,5.88 - 12.89,12.90 - 26.08,26.09 - 44.99,45.00 - 59.25,59.26 - 73.32,73.33 - 88.56,88.57 - 96.76,>= 96.77,No
Dementia: Functional Status Assessment,282,Registry/QCDR,Process,Y,57.14 - 78.94,78.95 - 95.27,95.28 - 99.12,99.13 - 99.99,--,--,--,100,Yes
Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management,283,Registry/QCDR,Process,Y,58.14 - 83.07,83.08 - 96.66,96.67 - 99.81,99.82 - 99.99,--,--,--,100,Yes
Dementia: Safety Concerns Screening and Mitigation Recommendations or Referral for Patients with Dementia,286,Registry/QCDR,Process,Y,62.86 - 78.68,78.69 - 89.88,89.89 - 98.20,98.21 - 99.99,--,--,--,100,Yes
Dementia: Caregiver Education and Support,288,Registry/QCDR,Process,Y,59.26 - 77.32,77.33 - 89.32,89.33 - 97.53,97.54 - 99.99,--,--,--,100,Yes
Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease,290,Registry/QCDR,Process,Y,85.09 - 92.55,92.56 - 96.91,96.92 - 99.22,99.23 - 99.99,--,--,--,100,Yes
Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment,291,Registry/QCDR,Process,Y,86.49 - 94.99,95.00 - 99.99,--,--,--,--,--,100,Yes
Parkinson's Disease: Rehabilitative Therapy Options,293,Registry/QCDR,Process,Y,67.03 - 82.94,82.95 - 94.28,94.29 - 99.99,--,--,--,--,100,Yes
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery,303,Registry/QCDR,Patient Reported Outcome,Y,45.11 - 70.87,70.88 - 78.76,78.77 - 84.90,84.91 - 91.77,91.78 - 98.79,98.80 - 99.99,--,100,No
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery,304,Registry/QCDR,Patient Engagement Experience,Y,50.00 - 72.21,72.22 - 80.29,80.30 - 87.08,87.09 - 95.41,95.42 - 99.11,99.12 - 99.99,--,100,No
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,EHR,Process,Y,0.31 - 0.41,0.42 - 0.67,0.68 - 1.02,1.03 - 1.34,1.35 - 2.23,2.24 - 3.84,3.85 - 6.90,>= 6.91,No
Cervical Cancer Screening,309,EHR,Process,Y,9.83 - 16.79,16.80 - 23.65,23.66 - 31.53,31.54 - 39.71,39.72 - 48.30,48.31 - 57.62,57.63 - 72.60,>= 72.61,No
Chlamydia Screening for Women,310,EHR,Process,Y,16.67 - 22.30,22.31 - 28.04,28.05 - 33.32,33.33 - 39.12,39.13 - 44.77,44.78 - 53.13,53.14 - 63.77,>= 63.78,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,EHR,Process,Y,19.56 - 24.13,24.14 - 28.18,28.19 - 32.30,32.31 - 36.66,36.67 - 42.11,42.12 - 50.69,50.70 - 74.54,>= 74.55,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Claims,Process,Y,34.25 - 45.47,45.48 - 58.48,58.49 - 73.28,73.29 - 89.40,89.41 - 98.06,98.07 - 99.99,--,100,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Registry/QCDR,Process,Y,25.75 - 30.80,30.81 - 35.46,35.47 - 42.56,42.57 - 59.14,59.15 - 83.48,83.49 - 97.31,97.32 - 99.99,100,No
Falls: Screening for Future Fall Risk,318,cmsWebInterface,Process,Y,0 - 43.42,43.42 - 50.42,50.42 - 58.45,58.45 - 66,66 - 73.39,73.39 - 81.79,81.79 - 90.73,>= 90.73,No
Falls: Screening for Future Fall Risk,318,EHR,Process,Y,7.24 - 20.26,20.27 - 36.40,36.41 - 52.24,52.25 - 66.72,66.73 - 78.59,78.60 - 88.50,88.51 - 96.55,>= 96.56,No
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Claims,Process,Y,95.24 - 97.72,97.73 - 99.99,--,--,--,--,--,100,Yes
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Registry/QCDR,Process,Y,85.00 - 89.73,89.74 - 93.60,93.61 - 95.94,95.95 - 97.72,97.73 - 98.95,98.96 - 99.99,--,100,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,322,Registry/QCDR,Efficiency,Y,1.90 - 0.01,--,--,--,--,--,--,0,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),323,Registry/QCDR,Efficiency,Y,2.44 - 0.01,--,--,--,--,--,--,0,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,Registry/QCDR,Efficiency,Y,6.25 - 2.02,2.01 - 0.01,--,--,--,--,--,0,Yes
Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions,325,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Claims,Process,Y,84.13 - 95.28,95.29 - 98.79,98.80 - 99.99,--,--,--,--,100,Yes
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Registry/QCDR,Process,Y,69.54 - 75.10,75.11 - 78.89,78.90 - 83.08,83.09 - 88.16,88.17 - 94.93,94.94 - 99.99,--,100,No
Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL,328,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis,329,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days,330,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse),331,Registry/QCDR,Process,Y,92.15 - 87.51,87.50 - 82.89,82.88 - 75.37,75.36 - 64.36,64.35 - 46.68,46.67 - 20.00,19.99 - 0.01,0,No
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,Registry/QCDR,Process,Y,93.55 - 96.19,96.20 - 97.58,97.59 - 98.39,98.40 - 99.35,99.36 - 99.99,--,--,100,Yes
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse),333,Registry/QCDR,Efficiency,Y,2.50 - 0.91,0.90 - 0.27,0.26 - 0.01,--,--,--,--,0,Yes
Maternity Care: Elective Delivery or Early Induction Without Medical Indication at >= 37 and < 39 Weeks (Overuse),335,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Maternity Care: Post-Partum Follow-Up and Care Coordination,336,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier",337,Registry/QCDR,Process,Y,47.06 - 60.60,60.61 - 73.62,73.63 - 82.50,82.51 - 89.99,90.00 - 96.42,96.43 - 99.99,--,100,No
HIV Viral Load Suppression,338,Registry/QCDR,Outcome,Y,74.47 - 78.56,78.57 - 83.99,84.00 - 87.93,87.94 - 93.99,94.00 - 97.23,97.24 - 99.99,--,100,No
HIV Medical Visit Frequency,340,Registry/QCDR,Process,Y,48.97 - 52.85,52.86 - 61.08,61.09 - 82.68,82.69 - 87.99,88.00 - 92.85,92.86 - 95.91,95.92 - 99.99,100,No
Pain Brought Under Control Within 48 Hours,342,Registry/QCDR,Outcome,Y,98.78 - 99.99,--,--,--,--,--,--,100,Yes
Screening Colonoscopy Adenoma Detection Rate,343,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)",344,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) Who Are Stroke Free or Discharged Alive,345,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA) Who Are Stroke Free or Discharged Alive,346,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Are Discharged Alive,347,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate,348,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,Registry/QCDR,Process,Y,96.00 - 99.99,--,--,--,--,--,--,100,Yes
Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet,352,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report,353,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Anastomotic Leak Intervention,354,Registry/QCDR,Outcome,Y,3.61 - 3.24,3.23 - 0.74,0.73 - 0.01,--,--,--,--,0,Yes
Unplanned Reoperation within the 30 Day Postoperative Period,355,Registry/QCDR,Outcome,Y,3.15 - 2.28,2.27 - 1.22,1.21 - 0.41,0.40 - 0.01,--,--,--,0,Yes
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,Registry/QCDR,Outcome,Y,5.00 - 3.31,3.30 - 2.01,2.00 - 0.01,--,--,--,--,0,Yes
Surgical Site Infection (SSI),357,Registry/QCDR,Outcome,Y,3.48 - 2.28,2.27 - 0.94,0.93 - 0.01,--,--,--,--,0,Yes
Patient-Centered Surgical Risk Assessment and Communication,358,Registry/QCDR,Process,Y,17.29 - 61.78,61.79 - 91.42,91.43 - 97.63,97.64 - 99.99,--,--,--,100,Yes
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,Registry/QCDR,Process,Y,31.53 - 61.37,61.38 - 90.54,90.55 - 98.82,98.83 - 99.99,--,--,--,100,Yes
Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry,361,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100,Yes
Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison,362,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100,Yes
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,Registry/QCDR,Process,Y,59.02 - 93.24,93.25 - 97.64,97.65 - 99.80,99.81 - 99.99,--,--,--,100,Yes
Follow-Up Care for Children Prescribed ADHD Medication (ADD),366,EHR,Process,Y,26.67 - 30.86,30.87 - 33.95,33.96 - 38.09,38.10 - 46.45,46.46 - 48.83,48.84 - 54.54,54.55 - 65.90,>= 65.91,No
Depression Remission at Twelve Months,370,EHR,Outcome,Y,2.08 - 2.69,2.70 - 3.69,3.70 - 4.34,4.35 - 5.31,5.32 - 7.13,7.14 - 8.76,8.77 - 14.99,>= 15.00,No
Depression Remission at Twelve Months,370,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression Utilization of the PHQ-9 Tool,371,EHR,Process,Y,3.82 - 6.11,6.12 - 9.08,9.09 - 12.68,12.69 - 16.66,16.67 - 22.08,22.09 - 30.29,30.30 - 43.13,>= 43.14,No
Maternal Depression Screening,372,EHR,Process,N,--,--,--,--,--,--,--,--,--
Closing the Referral Loop: Receipt of Specialist Report,374,EHR,Process,Y,7.63 - 14.97,14.98 - 26.32,26.33 - 36.73,36.74 - 48.14,48.15 - 60.24,60.25 - 74.43,74.44 - 90.74,>= 90.75,No
Closing the Referral Loop: Receipt of Specialist Report,374,Registry/QCDR,Process,Y,6.77 - 8.50,8.51 - 37.83,37.84 - 62.85,62.86 - 82.42,82.43 - 88.88,88.89 - 92.73,92.74 - 99.01,>= 99.02,No
Functional Status Assessment for Total Knee Replacement,375,EHR,Process,Y,5.00 - 9.67,9.68 - 15.90,15.91 - 20.30,20.31 - 24.55,24.56 - 34.37,34.38 - 53.41,53.42 - 77.26,>= 77.27,No
Functional Status Assessment for Total Hip Replacement,376,EHR,Process,Y,4.82 - 8.50,8.51 - 13.09,13.10 - 19.22,19.23 - 27.58,27.59 - 33.32,33.33 - 40.18,40.19 - 63.48,>= 63.49,No
Functional Status Assessments for Congestive Heart Failure,377,EHR,Process,N,--,--,--,--,--,--,--,--,--
Children Who Have Dental Decay or Cavities,378,EHR,Outcome,Y,0.47 - 0.10,0.09 - 0.01,--,--,--,--,--,0,Yes
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,EHR,Process,Y,0.32 - 0.54,0.55 - 0.73,0.74 - 1.08,1.09 - 2.07,2.08 - 3.21,3.22 - 4.89,4.90 - 9.04,>= 9.05,No
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,EHR,Process,Y,3.43 - 7.00,7.01 - 12.46,12.47 - 14.83,14.84 - 20.25,20.26 - 29.00,29.01 - 36.10,36.11 - 51.71,>= 51.72,No
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,Registry/QCDR,Intermediate Outcome,Y,58.00 - 71.42,71.43 - 86.83,86.84 - 90.00,90.01 - 98.32,98.33 - 99.99,--,--,100,No
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences,386,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users,387,Registry/QCDR,Process,Y,0.38 - 0.45,0.46 - 0.58,0.59 - 0.76,0.77 - 1.31,1.32 - 1.40,1.41 - 1.60,1.61 - 2.86,>= 2.87,No
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy),388,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0,Yes
Cataract Surgery: Difference Between Planned and Final Refraction,389,Registry/QCDR,Outcome,Y,77.17 - 90.90,90.91 - 96.96,96.97 - 99.21,99.22 - 99.99,--,--,--,100,No
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options,390,Registry/QCDR,Process,Y,63.64 - 80.86,80.87 - 95.44,95.45 - 99.99,--,--,--,--,100,Yes
Follow-Up After Hospitalization for Mental Illness (FUH),391,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation,392,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"HRS-9: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision",393,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Immunizations for Adolescents,394,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Lung Cancer Reporting (Resection Specimens),396,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Lung Cancer Reporting (Resection Specimens),396,Claims,Process,N,--,--,--,--,--,--,--,--,--
Melanoma Reporting,397,Claims,Process,Y,--,--,--,--,--,--,--,100,Yes
Melanoma Reporting,397,Registry/QCDR,Process,Y,91.96 - 99.99,--,--,--,--,--,--,100,Yes
Optimal Asthma Control,398,Registry/QCDR,Outcome,Y,33.52 - 59.45,59.46 - 74.99,75.00 - 95.99,96.00 - 98.98,98.99 - 99.99,--,--,100,No
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk,400,Registry/QCDR,Process,Y,1.26 - 1.84,1.85 - 3.22,3.23 - 6.30,6.31 - 16.77,16.78 - 24.10,24.11 - 32.00,32.01 - 74.59,>= 74.60,No
Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis,401,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Tobacco Use and Help with Quitting Among Adolescents,402,Registry/QCDR,Process,Y,86.36 - 91.17,91.18 - 94.11,94.12 - 96.11,96.12 - 97.58,97.59 - 98.83,98.84 - 99.99,--,100,Yes
Adult Kidney Disease: Referral to Hospice,403,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Anesthesiology Smoking Abstinence,404,Registry/QCDR,Intermediate Outcome,Y,39.88 - 50.58,50.59 - 57.24,57.25 - 62.99,63.00 - 69.74,69.75 - 75.26,75.27 - 82.40,82.41 - 93.37,>= 93.38,No
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Claims,Process,Y,10.26 - 4.45,4.44 - 0.73,0.72 - 0.01,--,--,--,--,0,Yes
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Registry/QCDR,Process,Y,12.11 - 6.68,6.67 - 2.64,2.63 - 0.54,0.53 - 0.01,--,--,--,0,Yes
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Claims,Process,Y,61.90 - 48.01,48.00 - 37.51,37.50 - 15.57,15.56 - 2.57,2.56 - 0.01,--,--,0,No
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Registry/QCDR,Process,Y,14.94 - 5.98,5.97 - 3.65,3.64 - 0.10,0.09 - 0.01,--,--,--,0,Yes
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia,407,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Appropriate Treatment of Methicillin-Sensitive Staphylococcus Aureus (MSSA) Bacteremia,407,Claims,Process,N,--,--,--,--,--,--,--,--,--
Opioid Therapy Follow-up Evaluation,408,Registry/QCDR,Process,Y,68.35 - 91.35,91.36 - 98.48,98.49 - 99.99,--,--,--,--,100,Yes
Clinical Outcome Post Endovascular Stroke Treatment,409,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Psoriasis: Clinical Response to Oral Systemic or Biologic Medications,410,Registry/QCDR,Outcome,Y,23.08 - 36.35,36.36 - 49.99,50.00 - 61.53,61.54 - 72.21,72.22 - 87.49,87.50 - 97.21,97.22 - 99.99,100,No
Depression Remission at Six Months,411,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Documentation of Signed Opioid Treatment Agreement,412,Registry/QCDR,Process,Y,61.17 - 88.34,88.35 - 97.43,97.44 - 99.66,99.67 - 99.99,--,--,--,100,Yes
Door to Puncture Time for Endovascular Stroke Treatment,413,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Evaluation or Interview for Risk of Opioid Misuse,414,Registry/QCDR,Process,Y,88.55 - 98.59,98.60 - 99.99,--,--,--,--,--,100,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Claims,Efficiency,Y,96.00 - 99.99,--,--,--,--,--,--,100,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Registry/QCDR,Efficiency,Y,63.41 - 69.99,70.00 - 76.18,76.19 - 80.36,80.37 - 83.45,83.46 - 86.48,86.49 - 89.60,89.61 - 98.20,>= 98.21,No
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Registry/QCDR,Efficiency,Y,46.67 - 40.01,40.00 - 35.01,35.00 - 28.38,28.37 - 22.82,22.81 - 18.76,18.75 - 14.82,14.81 - 9.53,<= 9.52,No
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Claims,Efficiency,N,--,--,--,--,--,--,--,--,--
Rate of Open Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) Where Patients Are Discharged Alive,417,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Osteoporosis Management in Women Who Had a Fracture,418,Claims,Process,N,--,--,--,--,--,--,--,--,--
Osteoporosis Management in Women Who Had a Fracture,418,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Overuse of Imaging for the Evaluation of Primary Headache,419,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Overuse of Imaging for the Evaluation of Primary Headache,419,Claims,Process,N,--,--,--,--,--,--,--,--,--
Varicose Vein Treatment with Saphenous Ablation: Outcome Survey,420,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal,421,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Claims,Process,N,--,--,--,--,--,--,--,--,--
Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury,422,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Perioperative Temperature Management,424,Registry/QCDR,Outcome,Y,98.46 - 99.51,99.52 - 99.74,99.75 - 99.87,99.88 - 99.99,--,--,--,100,Yes
Photodocumentation of Cecal Intubation,425,Claims,Process,Y,97.44 - 98.48,98.49 - 99.15,99.16 - 99.99,--,--,--,--,100,Yes
Photodocumentation of Cecal Intubation,425,Registry/QCDR,Process,Y,97.59 - 98.31,98.32 - 98.73,98.74 - 99.04,99.05 - 99.29,99.30 - 99.50,99.51 - 99.76,99.77 - 99.99,100,Yes
Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence,428,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Claims,Process,N,--,--,--,--,--,--,--,--,--
Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy,429,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,Registry/QCDR,Process,Y,93.66 - 97.17,97.18 - 98.53,98.54 - 99.21,99.22 - 99.63,99.64 - 99.91,99.92 - 99.99,--,100,Yes
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,Registry/QCDR,Process,Y,33.43 - 49.34,49.35 - 66.11,66.12 - 78.12,78.13 - 86.99,87.00 - 93.51,93.52 - 97.95,97.96 - 99.99,100,No
Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair,432,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair,433,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion of Patients Sustaining a Ureter Injury at the Time of any Pelvic Organ Prolapse Repair,434,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Registry/QCDR,Patient Reported Outcome,Y,2.05 - 3.02,3.03 - 5.49,5.50 - 12.43,12.44 - 25.81,25.82 - 75.85,75.86 - 99.99,--,100,No
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Claims,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Claims,Process,Y,85.73 - 94.12,94.13 - 97.45,97.46 - 98.95,98.96 - 99.65,99.66 - 99.99,--,--,100,Yes
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Registry/QCDR,Process,Y,93.28 - 96.96,96.97 - 99.05,99.06 - 99.66,99.67 - 99.91,99.92 - 99.99,--,--,100,Yes
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Claims,Outcome,Y,1.32 - 0.56,0.55 - 0.01,--,--,--,--,--,0,Yes
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,EHR,Process,Y,63.75 - 71.06,71.07 - 77.11,77.12 - 84.26,84.27 - 99.99,--,--,--,100,No
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,Registry/QCDR,Process,Y,78.72 - 91.66,91.67 - 95.64,95.65 - 97.37,97.38 - 99.99,--,--,--,100,Yes
Age Appropriate Screening Colonoscopy,439,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time - Pathologist to Clinician,440,Registry/QCDR,Process,Y,96.91 - 98.95,98.96 - 99.87,99.88 - 99.99,--,--,--,--,100,Yes
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,Registry/QCDR,Intermediate Outcome,Y,32.40 - 37.13,37.14 - 40.16,40.17 - 44.03,44.04 - 47.77,47.78 - 50.61,50.62 - 54.35,54.36 - 58.25,>= 58.26,No
Persistence of Beta-Blocker Treatment After a Heart Attack,442,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Management for People with Asthma,444,Registry/QCDR,Process,Y,91.67 - 95.99,96.00 - 97.77,97.78 - 98.43,98.44 - 99.99,--,--,--,100,Yes
Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG),445,Registry/QCDR,Outcome,Y,3.90 - 3.17,3.16 - 2.69,2.68 - 2.25,2.24 - 1.73,1.72 - 1.23,1.22 - 0.01,--,0,No
Operative Mortality Stratified by the Five STS-EACTS Mortality Categories,446,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Work Up Prior to Endometrial Ablation,448,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies,449,Registry/QCDR,Process,Y,95.71 - 98.52,98.53 - 99.99,--,--,--,--,--,100,Yes
Trastuzumab Received By Patients With AJCC Stage I (T1c) -  III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy,450,Registry/QCDR,Process,Y,90.00 - 90.90,90.91 - 93.54,93.55 - 99.99,--,--,--,--,100,Yes
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy,451,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies,452,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion Receiving Chemotherapy in the Last 14 Days of Life,453,Registry/QCDR,Process,Y,15.00 - 10.43,10.42 - 9.19,9.18 - 8.00,7.99 - 7.36,7.35 - 7.04,7.03 - 2.39,2.38 - 0.01,0,No
Proportion of Patients who Died from Cancer with more than One Emergency Department Visit in the Last 30 Days of Life,454,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life,455,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Proportion Not Admitted To Hospice,456,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Proportion Admitted to Hospice for less than 3 days,457,Registry/QCDR,Outcome,Y,15.38 - 15.01,15.00 - 13.52,13.51 - 11.11,11.10 - 9.65,9.64 - 6.46,6.45 - 0.01,--,0,No
Average Change in Back Pain following Lumbar Discectomy / Laminotomy,459,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Average Change in Back Pain following Lumbar Fusion,460,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Average Change in Leg Pain following Lumbar Discectomy and/or Laminotomy,461,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy,462,EHR,Process,N,--,--,--,--,--,--,--,--,--
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion (OME): Systemic Antimicrobials- Avoidance of Inappropriate Use,464,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and.Interrogation of Ovarian Arteries,465,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Developmental Screening in the First Three Years of Life,467,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Continuity of Pharmacotherapy for Opioid Use Disorder (OUD),468,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Average Change in Functional Status Following Lumbar Fusion Surgery,469,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Average Change In Functional Status Following Total Knee Replacement Surgery,470,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Average Change in Functional Status Following Lumbar Discectomy/Laminotomy Surgery,471,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture,472,EHR,Process,N,--,--,--,--,--,--,--,--,--
Average Change in Leg Pain Following Lumbar Fusion Surgery,473,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Zoster (Shingles) Vaccination,474,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HIV Screening,475,EHR,Process,N,--,--,--,--,--,--,--,--,--
Asthma Assessment and Classification,AAAAI11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lung Function/Spirometry Evaluation,AAAAI12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Asthma Control: Minimal Important Difference Improvement,AAAAI17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Penicillin Allergy: Appropriate Removal or Confirmation,AAAAI18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Asthma: Assessment of Asthma Control � Ambulatory Care Setting,AAAAI2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of Clinical Response to Allergen Immunotherapy within One Year,AAAAI6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year ,AAAAI8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s) ,AAAAI9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Psoriasis: Assessment of Psoriasis Disease Activity,AAD1,Registry/QCDR,Process,Y,10.16 - 18.74,18.75 - 25.12,25.13 - 35.83,35.84 - 43.47,43.48 - 57.07,57.08 - 76.76,76.77 - 99.99,100,No
Psoriasis: Screening for Psoriatic Arthritis,AAD2,Registry/QCDR,Process,Y,82.44 - 95.44,95.45 - 99.99,--,--,--,--,--,100,Yes
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients,AAD3,Registry/QCDR,Process,Y,1.58 - 0.01,--,--,--,--,--,--,0,Yes
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk,AAD4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Biopsy: Reporting Time - Clinician to Patient,AAD5,Registry/QCDR,Process,Y,73.58 - 90.13,90.14 - 98.61,98.62 - 99.99,--,--,--,--,100,Yes
Diabetes/Pre-Diabetes Screening for Patients with DSP,AAN1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Falls screening (aggregation of AAN disease specific falls measures),AAN10,Registry/QCDR,Process,Y,4.09 - 11.95,11.96 - 22.21,22.22 - 30.42,30.43 - 53.84,53.85 - 65.26,65.27 - 81.94,81.95 - 90.33,>= 90.34,No
Overuse of barbiturate and opioid containing medications for primary headache disorders ,AAN11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment for Patients with Epilepsy,AAN12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Current MS Disability Scale Score,AAN14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Quality of Life Assessment,AAN15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Falls Outcome for Patients with Parkinson's Disease,AAN16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
First line treatment for infantile spasms (IS),AAN18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Botulinum Toxin Serotype A (BoNT-A) for spasticity or dystonia,AAN19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
DSP Screening for Unhealthy Alcohol Use ,AAN2,Registry/QCDR,Process,Y,42.45 - 46.26,46.27 - 47.02,47.03 - 49.31,49.32 - 52.30,52.31 - 53.46,53.47 - 55.12,55.13 - 59.18,>= 59.19,No
Querying for co-morbid conditions of tic disorder (TD) and Tourette syndrome (TS),AAN20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening for Psychiatric or Behavioral Health Disorders,AAN4,Registry/QCDR,Process,Y,27.59 - 41.34,41.35 - 58.32,58.33 - 74.06,74.07 - 83.90,83.91 - 94.11,94.12 - 98.13,98.14 - 99.73,>= 99.74,No
MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK,AAN5,Registry/QCDR,Process,Y,14.50 - 16.66,16.67 - 22.40,22.41 - 28.43,28.44 - 32.46,32.47 - 40.19,40.20 - 45.50,45.51 - 53.00,>= 53.01,No
Exercise and Appropriate Physical Activity Counseling for Patients with MS,AAN8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Querying About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease ,AAN9,Registry/QCDR,Process,Y,61.54 - 82.60,82.61 - 92.85,92.86 - 94.58,94.59 - 97.49,97.50 - 99.99,--,--,100,No
Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids,AAO11,Registry/QCDR,Process,Y,99.60 - 99.99,--,--,--,--,--,--,100,Yes
Topical Ear Drop Monotherapy for Children with Acute Tympanostomy Tube Otorrhea ,AAO12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inappropriate Use of Magnetic Resonance Imaging or Computed Tomography Scan for Bell�s Palsy (Inverse Measure),AAO13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Inappropriate Use of Antiviral Monotherapy for Bell�s Palsy (Inverse Measure),AAO14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with cerumen impaction and a suggestive history of a non-intact tympanic membrane who receive just manual removal.,AAO15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Audiometric Evaluation for Older Adults with Hearing Loss ,AAO16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss-Avoidance of Inappropriate Use ,AAO17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of visits with patients with hearing aids where otoscopy is routinely performed,AAO18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Shared Decision Making for Treatment Options for Bilateral Presbycusis or Symmetric Sensorineural Hearing Loss,AAO19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Hearing Testing,AAO20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Audiometry for Chronic Otitis Media with Effusion in Children,AAO21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who do not receive sinonasal imaging for allergic rhinitis ,AAO22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who are offered intranasal corticosteroids or oral antihistamines,AAO23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who do not receive leukotriene inhibitors,AAO24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percentage of patients with allergic rhinitis who do not receive IgG-based immunoglobulin testing,AAO25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility,AAO26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Children,AAO27,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Resolution of Otitis Media with Effusion in Adults,AAO28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Otitis Media with Effusion: Antihistamines or Decongestants � Avoidance of Inappropriate Use,AAO8,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
All Patients Who Die an Expected Death with an ICD that Has Been Deactivated,ABFM1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients Admitted to ICU who Have Care Preferences Documented,ABFM2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patients Treated with an Opioid Who Are Given a Bowel Regimen,ABFM3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Palliative Care � Spiritual Assessment,ABFM4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Palliative Care�Treatment Preferences,ABFM5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Palliative Care Timely Dyspnea Screening & Treatment,ABFM6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pain Brought Under Control within the first three visits,ABFM7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Measuring the Value-Functions of Primary Care: Provider Level Continuity Measure,ABFM8,Registry/QCDR,Structure,N,--,--,--,--,--,--,--,--,--
Intra-operative anesthesia safety,ABG1,Registry/QCDR,Outcome,Y,99.98 - 99.99,--,--,--,--,--,--,100,Yes
Planned use of difficult airway equipment,ABG16,Registry/QCDR,Process,Y,56.01 - 61.14,61.15 - 72.26,72.27 - 77.96,77.97 - 82.24,82.25 - 89.40,89.41 - 94.18,94.19 - 99.83,>= 99.84,No
Pre-operative OSA assessment,ABG21,Registry/QCDR,Process,Y,29.34 - 48.18,48.19 - 62.50,62.51 - 84.86,84.87 - 90.41,90.42 - 95.13,95.14 - 99.76,99.77 - 99.99,100,No
Pre-Operative Screening for GERD,ABG28,Registry/QCDR,Process,Y,32.09 - 44.87,44.88 - 50.15,50.16 - 52.83,52.84 - 58.27,58.28 - 87.25,87.26 - 98.87,98.88 - 99.99,100,No
Pre-Operative Screening for Glaucoma,ABG29,Registry/QCDR,Process,Y,44.29 - 67.22,67.23 - 95.02,95.03 - 99.50,99.51 - 99.99,--,--,--,100,Yes
Pre-Operative Screening for PONV Risk,ABG30,Registry/QCDR,Process,Y,76.64 - 93.46,93.47 - 97.59,97.60 - 99.05,99.06 - 99.66,99.67 - 99.99,--,--,100,Yes
Pre-Operative Screening for Excessive Alcohol and Recreational Drug Use,ABG31,Registry/QCDR,Process,Y,89.72 - 98.87,98.88 - 99.66,99.67 - 99.97,99.98 - 99.99,--,--,--,100,Yes
Pain Related Quality of Life Interference,ABG32,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Lower Body Functional Impairment (LBI),ABG33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mood Assessment Screening and treatment ,ABG34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Assessment of Frailty,ABG35,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Corneal Abrasion,ABG36,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Immediate Adult Post-Operative Pain Management,ABG7,Registry/QCDR,Outcome,Y,97.85 - 98.62,98.63 - 99.28,99.29 - 99.82,99.83 - 99.99,--,--,--,100,Yes
ACCPin3 Heart Failure: Patient Self Care Education,ACCPIN3,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,ACEP19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,ACEP20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ACEP21,Registry/QCDR,Process,Y,24.61 - 19.33,19.32 - 15.93,15.92 - 9.06,9.05 - 5.75,5.74 - 3.78,3.77 - 0.01,--,0,No
Appropriate Emergency Department Utilization of CT for Pulmonary Embolism,ACEP22,Registry/QCDR,Process,Y,8.00 - 14.99,15.00 - 18.95,18.96 - 22.72,22.73 - 26.55,26.56 - 29.46,29.47 - 36.66,36.67 - 50.58,>= 50.59,No
Pregnancy Test for Female Abdominal Pain Patients,ACEP24,Registry/QCDR,Process,Y,55.27 - 60.22,60.23 - 64.28,64.29 - 68.37,68.38 - 73.24,73.25 - 77.93,77.94 - 80.55,80.56 - 84.76,>= 84.77,No
Tobacco Use: Screening and Cessation Intervention for Patients with Asthma and COPD,ACEP25,Registry/QCDR,Process,Y,63.89 - 67.52,67.53 - 71.87,71.88 - 74.99,75.00 - 78.78,78.79 - 81.81,81.82 - 85.70,85.71 - 89.99,>= 90.00,No
Sepsis Management: Septic Shock: Repeat Lactate Level Measurement,ACEP29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sepsis Management: Septic Shock: Lactate Clearance Rate of >=10%,ACEP30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Foley Catheter Use in the Emergency Department,ACEP31,Registry/QCDR,Process,Y,43.04 - 51.99,52.00 - 59.08,59.09 - 63.36,63.37 - 69.04,69.05 - 73.07,73.08 - 88.09,88.10 - 91.66,>= 91.67,No
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients,ACEP32,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Supercenter EDs
(80k +)",ACEP33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in High Volume EDs (60k-79,999)",ACEP35,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Average Volume EDs (40k-59,999)",ACEP36,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Moderate Volume EDs (20k-39,999)",ACEP37,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Low Volume EDs (19,999 and less)",ACEP38,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients in Freestanding Ends,ACEP39,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients,ACEP40,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Supercenter EDs (80k +),ACEP41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in High Volume EDs (60k-79,999)",ACEP43,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Average Volume EDs (40k-59,999)",ACEP44,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Moderate Volume EDs (20k-39,999)",ACEP45,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Low Volume EDs (19,999 and less)",ACEP46,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients in Freestanding EDs,ACEP47,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Sepsis Management: Septic Shock: Lactate Level Management, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening for risk of opioid misuse/overuse,ACMT1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pregnancy test in women who receive a toxicologic consult,ACMT2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
EKG assessment in acute overdoses,ACMT3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate treatment for acetaminophen ingestions,ACMT4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment of suspected ethylene glycol or methanol exposures,ACMT5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Repeat assessment of salicylate concentrations in overdose patients,ACMT6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
High Risk Pneumococcal Vaccination,ACPGR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Tdap (Tetanus, Diphtheria, Acellular Pertussis) Vaccination",ACPGR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy,ACPGR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COPD Exacerbation Requiring Hospital Admission: Palliative Care Evaluation,ACQR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COPD Exacerbation: % of patients discharged from inpatient status on Long Acting Beta Agonist (LABA) bronchodilator,ACQR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COPD: Steroids for no more than 5 days in COPD Exacerbation,ACQR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CHF Exacerbation Requiring Hospital Admission: Palliative Care Evaluation,ACQR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CHF: Document AHA/ACC staging of CHF (A-D),ACQR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"POLST Utilization: POLST form reviewed or completed for any patients with limited code status (i.e. any status other than, ""Attempt Resuscitation"" if unresponsive, pulseless and not breathing;  and ""Full Treatment"" if patient is pulseless and breathing)",ACQR6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Sepsis Management: Septic Shock: Repeat Lactate Level Measurement within 6 hours,ACQR7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Stroke/TIA: % of patients discharged on antithrombotic therapy,ACQR8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Gout: Serum Urate Target ,ACR7,Registry/QCDR,Intermediate Outcome,Y,21.19 - 28.09,28.10 - 34.77,34.78 - 38.16,38.17 - 41.88,41.89 - 46.53,46.54 - 58.87,58.88 - 67.14,>= 67.15,No
CT Colonography True Positive Rate,ACRAD1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: Radiography (modified),ACRAD15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: MRI,ACRAD17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: CT,ACRAD18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: PET,ACRAD19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Cancer Detection Rate (CDR),ACRAD21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lung Cancer Screening Positive Predictive Value (PPV),ACRAD22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Report Turnaround Time: Mammography,ACRAD25,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate venous access for hemodialysis,ACRAD26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of early peristomal infection following fluoroscopically guided gastrostomy tube placement,ACRAD28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of percutaneous nephrostomy tube replacement within 30 days secondary to dislodgement,ACRAD29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Cancer Detection Rate (CDR),ACRAD3,Registry/QCDR,Outcome,Y,0.18 - 0.23,0.24 - 0.30,0.31 - 0.42,0.43 - 0.48,0.49 - 0.53,0.54 - 0.61,0.62 - 0.79,>= 0.80,No
Rate of Inadequate Percutaneous Image-Guided Biopsy,ACRAD30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of CT Abdomen-pelvis exams with contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD31,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100,Yes
Percent of CT Chest exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD32,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100,Yes
Percent of CT Head/Brain exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level,ACRAD33,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100,Yes
Screening Mammography Positive Predictive Value 2 (PPV2 - Biopsy Recommended),ACRAD6,Registry/QCDR,Outcome,Y,20.00 - 21.61,21.62 - 23.07,23.08 - 26.08,26.09 - 29.89,29.90 - 31.99,32.00 - 35.58,35.59 - 37.15,>= 37.16,No
Screening Mammography Node Negativity Rate,ACRAD7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening Mammography Minimal Cancer Rate,ACRAD8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Composite,ACS15,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Preventative Care and Screening: Tobacco Screening and Cessation Intervention,ACS16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative Key Medications Review for Anticoagulation Medication,ACS17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Frailty Evaluation,ACS18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Intraoperative Composite ,ACS19,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Optimal Postoperative Communication Plan and Patient Care Coordination Composite,ACS20,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Post-Acute Recovery Composite,ACS21,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Unplanned Reoperation within the 30 Day Postoperative Period,ACS22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission within 30 Days of Principal Procedure,ACS23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Phases of Care Patient-Reported Outcome Composite Measure,ACS24,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Surgical Site Infection (SSI),ACS25,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Trauma Initial Assessment Composite,ACSTRAUMA1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Mortality Rate Following Blunt Traumatic Injury to the Chest and/or Abdomen,ACSTRAUMA2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mortality Rate Following Penetrating Traumatic Injury to the Chest and/or Abdomen,ACSTRAUMA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Splenic Salvage Rate,ACSTRAUMA4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Optimal Timing of Surgical or Procedural Intervention for Hemorrhage in Trauma,ACSTRAUMA5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Optimal Ratio of Blood Product Transfusion,ACSTRAUMA6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Timely Initiation of VTE Prophylaxis in Trauma Patients,ACSTRAUMA7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Hospital Readmission or Observation Visit within the 30 Day Postoperative Period,AHSQC2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Abdominal Wall Reconstruction Surgical Site Occurrence Requiring Procedural Intervention within the 30 Day Postoperative Period,AHSQC6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Biologic Mesh Prosthesis Use in Low Risk Patients,AHSQC8,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Ventral Hernia Repair: Pain and Functional Status Assessment,AHSQC9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Postoperative Complications within 90 Days Following the Procedure,AJRR1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,AJRR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hip Arthroplasty: Venous Thromboembolic and Cardiovascular Risk Evaluation,AJRR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Comprehensive Diabetic Foot Examination,APMA1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Prolonged Intubation � Inverse Measure,AQI18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Stroke � Inverse Measure,AQI41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coronary Artery Bypass Graft (CABG): Post-Operative Renal Failure � Inverse Measure,AQI42,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient-Reported Experience with Anesthesia ,AQI48,Registry/QCDR,Patient Reported Outcome,Y,55.23 - 60.02,60.03 - 94.51,94.52 - 99.08,99.09 - 99.98,99.99 - 99.99,--,--,100,Yes
Adherence to Blood Conservation Guidelines for Cardiac Operations using Cardiopulmonary Bypass (CPB) � Composite,AQI49,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Application of Lung-Protective Ventilation during General Anesthesia,AQI50,Registry/QCDR,Intermediate Outcome,Y,99.14 - 99.45,99.46 - 99.82,99.83 - 99.99,--,--,--,--,100,Yes
Assessment of Patients for Obstructive Sleep Apnea,AQI51,Registry/QCDR,Process,Y,79.31 - 92.61,92.62 - 96.39,96.40 - 99.34,99.35 - 99.79,99.80 - 99.94,99.95 - 99.99,--,100,Yes
Documentation of Anticoagulant and Antiplatelet Medications when Performing Neuraxial Anesthesia/Analgesia or Interventional Pain Procedures,AQI53,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Pencil-Point Needle for Spinal Anesthesia,AQI54,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Team-Based Implementation of a Care-and-Communication Bundle for ICU Patients,AQI55,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA),AQI56,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Safe Opioid Prescribing Practices,AQI57,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Infection Control Practices for Open Interventional Pain Procedures,AQI58,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Multimodal Pain Management,AQI59,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
New Corneal Injury Not Diagnosed Prior to Discharge ,AQI60,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Benign Prostate Hyperplasia: IPSS improvement after diagnosis,AQUA12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stress Urinary Incontinence (SUI): Revision surgery within 12 months of incontinence procedure,AQUA13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stones: Repeat Shock Wave Lithotripsy (SWL) within 6 months of treatment,AQUA14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stones: Urinalysis documented 30 days before surgical stone procedures,AQUA15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease,AQUA16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Initiation of BCG 3 months of diagnosis of high-grade T1 bladder cancer and/or CIS,AQUA17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis,AQUA18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diagnosis of Type of Azoospermia and Diagnostic Testing for Obstructive Azoospermia,AQUA19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Genetic Testing  of the Azoospermic Male,AQUA20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Management of Obstructive Azoospermia,AQUA21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Bone imaging and soft tissue imaging at the time of diagnosis of metastatic CRPC,AQUA22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Blood work for patients receiving abiraterone,AQUA23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Testosterone and PSA levels checked for CRPC patients,AQUA24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Prednisone for CRPC patients on abiraterone,AQUA25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia,AQUA26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Testing for Vasectomy Patients,AQUA27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Hypogonadism: Testosterone and hematocrit within 6 months of starting testosterone replacement,AQUA28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Patient Report of Urinary function after treatment,AQUA29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cryptorchidism: Inappropriate use of scrotal/groin ultrasound on boys,AQUA3,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Patient Report of Sexual function after treatment,AQUA30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hospital admissions/complications within 30 days of TRUS Biopsy,AQUA8,Registry/QCDR,Outcome,Y,5.13 - 4.23,4.22 - 3.22,3.21 - 2.64,2.63 - 1.02,1.01 - 0.70,0.69 - 0.01,--,0,Yes
Risk Standardized Mortality Rate within 30 days following Trauma Operation,ARCO10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation within 45 minutes of ED Arrival,ARCO11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
STK-01: Venous Thromboembolism (VTE) Prophylaxis,ARCO12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
STK 02: Ischemic stroke patients management -�,ARCO13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Diabetes: Nutritional, Weight Loss Counseling, Reduction of Sedentary Behavior",ARCO15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Dyspnea or Heart Failure: Use of BNP or NT- pro BNP screening,ARCO16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Heart Failure: Use of Aldosterone Antagonists and Diuretics for Symptom Control,ARCO17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Heart Failure: Counseling on Self-care, Including Monitoring Blood Pressure, Weight, Sodium Intake, and Physical Activity",ARCO18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Promoting self-care for prevention and management of chronic conditions,ARCO19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Percentage of patients using self-monitoring with mobile technology or eHealth solutions to manage their diabetes, hypertension, sodium intake, nutritional status, physical activity, tobacco use, alcohol use, and sedentary behaviors",ARCO20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Antipsychotic Use in Persons with Dementia,ARCO3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgeon assessment for hereditary cause of breast cancer,ASBS1,Registry/QCDR,Process,Y,99.16 - 99.99,--,--,--,--,--,--,100,Yes
Management of the axilla in breast cancer patients undergoing breast conserving surgery with a positive sentinel node biopsy,ASBS10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Return to the operating room for re-excision of previous microscopically negative margins in invasive breast cancer patients undergoing breast conserving therapy ,ASBS12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Sentinel Node Biopsy for Patients with Ductal Carcinoma in Situ Alone ,ASBS13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Recommendation of Neoadjuvant Chemotherapy for Her2Neu positive invasive breast cancers that are >2.0cm in size and/or have needle biopsy proven axillary metastases. ,ASBS14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unplanned 30 day re-operation after mastectomy,ASBS7,Registry/QCDR,Outcome,Y,98.15 - 98.46,98.47 - 99.99,--,--,--,--,--,100,Yes
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients,ASNC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Imaging Protocols for SPECT and PET MPI studies - Use of stress only protocol,ASNC19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),ASNC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI studies performed without the use of thallium,ASNC20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study appropriate imaging protocol selection for morbidly obese patients,ASNC21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies reporting Left Ventricular Ejection Fraction,ASNC22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study clinical utilization of Attenuation Correction image acquisition,ASNC23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study utilization of exercise as a stressor,ASNC24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT-MPI study adequate exercise testing performed,ASNC25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies meeting appropriate use criteria,ASNC26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI studies not Equivocal,ASNC27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Effective dose less than or equal to 9 millisieverts as per ASNC guideline recommendations,ASNC28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SPECT and PET MPI study documentation of stress perfusion defects,ASNC29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Cardiac Stress Nuclear Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",ASNC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
" Transthoracic Echo (TTE) studies meeting appropriate use criteria
",ASNC30,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Transthoracic Echo (TTE) studies reporting pulmonary artery pressures, 100% views, contrast use  
",ASNC31,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Avoiding myocardial Injury ,ASPIRE18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoiding acute kidney injury,ASPIRE19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Train of Four Monitor Documented After Last Dose of Non-depolarizing Neuromuscular Blocker,ASPIRE2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Application of Lung-Protective Ventilation during General Anesthesia,ASPIRE6,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Information Provided during Breast Reconstruction,ASPS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Operative Time for Autologous Breast Reconstruction,ASPS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned hospital admission after panniculectomy,ASPS12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Wound disruption rate after primary panniculectomy in patients with BMI > or = to 35,ASPS13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Wound disruption rate after primary panniculectomy in patients with BMI < 35,ASPS14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Seroma rate after primary panniculectomy,ASPS15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Breast Reconstruction: Return to OR,ASPS5,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Breast Reconstruction: Flap Loss,ASPS6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Rate of Blood Transfusion for Patients Undergoing Autologous Breast Reconstruction,ASPS7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Coordination of Care for Patients Undergoing Breast Reconstruction,ASPS8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Length of Stay Following Autologous Breast Reconstruction,ASPS9,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Complete�assessment�and�evaluation�of patient�s�pelvic�organ�prolapse�prior�to surgical�repair,AUGS1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of offering a preoperative pessary for Pelvic Organ Prolapse,AUGS10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation that a trial of conservative management was offered prior to use of procedure based therapy for urgency urinary incontinence,AUGS11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative assessment of sexual function prior to pelvic organ prolapse repair,AUGS3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing an intraoperative rectal examination at the time of prolapse repair,AUGS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Performing vaginal apical suspension at the time of hysterectomy to address pelvic organ prolapse,AUGS5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Route of Hysterectomy,AUGS6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation that conservative management was offered prior to fecal incontinence surgery or procedures,AUGS7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Documentation of weight loss counseling prior to surgery for stress urinary incontinence procedures for obese women,AUGS8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Over-utilization of synthetic mesh in the posterior compartment,AUGS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Comprehensive Assessment of Safety,BIVARUS27,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Patient Reported Experience and Care Coordination,BIVARUS28,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Patient Reported Care Team Communication,BIVARUS32,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Procedure Readiness and Care ,BIVARUS33,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Turn-Around Time (TAT) - Standard biopsies,CAP1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma and Carcinosarcoma of the Endometrium,CAP2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Invasive Carcinoma of Renal Tubular Origin,CAP3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Intrahepatic Bile Ducts Completed,CAP4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Hepatocellular Carcinoma Completed,CAP5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Protocol Elements for Carcinoma of the Pancreas Completed,CAP6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Helicobacter pylori documentation rate,CAP7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Turn-Around Time (TAT) - Lactate,CAP8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Turn-Around Time (TAT) - Troponin,CAP9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Knee Arthroplasty,CCOME1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Hip Arthroplasty,CCOME2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after Total Shoulder Arthroplasty,CCOME3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after ACLR Surgery,CCOME4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Extent of Osteoarthritis Observed in Arthroscopic Partial Meniscectomy,CCOME5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
1-Year Patient-Reported Pain and Function Improvement after APM Surgery,CCOME6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adequate Off-loading of Diabetic Foot Ulcer at each visit,CDR1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Foot Ulcer (DFU) Healing or Closure ,CDR2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Plan of Care Creation for Diabetic Foot Ulcer (DFU) Patients not Achieving 30% Closure at 4 Weeks AND Plan of Care Creation for Venous Leg Ulcer (VLU) Patients not Achieving 30% Closure at 4 Weeks,CDR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequate Compression at each visit for Patients with VLUs ,CDR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Venous Leg Ulcer (VLU) outcome measure: Healing or Closure,CDR6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate Use of hyperbaric oxygen therapy for patients with diabetic foot ulcers,CDR8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Use of Cellular and/or Tissue Based Product (CTP) in diabetic foot ulcers (DFUs) or venous leg ulcer (VLUs) among patients 18 years or older,CDR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post operative hypocalcemia after thyroidectomy surgery,CESQIP1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Related readmission for thyroid or parathyroid related problems,CESQIP2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Pre operative ultrasound exam of patients with thyroid cancer,CESQIP3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Persistent hypercalcemia,CESQIP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Related readmission for adrenal related problems,CESQIP5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Vocal cord dysfunction following thyroidectomy,CESQIP7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Hematoma requiring evacuation following thyroidectomy,CESQIP8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Back Pain: Use of EMG & CNS,CLLC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Morton's Neuroma - Avoidance of Alcohol Injections,CLLC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cancer Patients - Survivorship Care Plan,CLLC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Foot Bone Infection Diagnosis Without MRI,CLLC4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Shoulder Replacement,CODE1,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Shoulder Arthroscopy,CODE10,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Knee Arthroscopy,CODE11,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Hip Arthroscopy,CODE12,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for ACL Repair,CODE2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Foot/Ankle Repair,CODE3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Spine Surgery,CODE5,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Hip Replacement,CODE6,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Functional Outcome Assessment for Knee Replacement,CODE7,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Cervical Surgery,CODE8,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improved Global Physical Health Outcome Assessment for Hand/Wrist/Elbow Repair,CODE9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"CAHPS Clinician/Group Surveys - (Adult Primary Care, Pediatric Care, and Specialist Care Surveys)",CUHSM3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
CAHPS Health Plan Survey v 4.0 - Adult questionnaire,CUHSM4,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder,CUHSM6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiovascular Health Screening for People With Schizophrenia or Bipolar Disorder Who Are Prescribed Antipsychotic Medications,CUHSM8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneEGFR,CURE1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneNSCLCBRAFTTP,CURE10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneMelBRAFTTP,CURE11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneALK,CURE2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneROS1,CURE3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneNSCLCBRAF,CURE4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOnePDL1,CURE5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneMelBRAF,CURE6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CureOneEGFRTTP,CURE7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneALKTTP,CURE8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CureOneROS1TTP,CURE9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Three Day All Cause Return ED Visit Rate,ECPR11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Door to Diagnostic Evaluation by a Provider � Emergency Department (ED) Patients,ECPR2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Lower Acuity ED Patients,ECPR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Time from Emergency Department (ED) Arrival to ED Departure for Discharged Higher Acuity ED Patients,ECPR6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,Registry/QCDR,Process,Y,83.33 - 84.77,84.78 - 87.17,87.18 - 88.44,88.45 - 90.90,90.91 - 92.67,92.68 - 94.43,94.44 - 96.98,>= 96.99,No
Initiation of the Initial Sepsis Bundle,ECPR40,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rh Status Evaluation and Treatment of Pregnant Women at Risk of Fetal Blood Exposure ,ECPR41,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Restrictive Use of Blood Transfusions,ECPR42,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Creatine Kinase-MB (CK-MB) Testing for Non-traumatic Chest Pain ,ECPR45,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Opiate Prescriptions for Low Back Pain or Migraines,ECPR46,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain ,ECPR47,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions ,ECPR48,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoidance of Tramadol or Codeine for Children,ECPR49,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Door to Diagnostic Evaluation by a Provider Within 30 Minutes � Urgent Care Patients,ECPR50,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Preoperative Frailty Assessment,EPREOP28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Preoperative Assessment for Opioid Dependence Risk ,EPREOP29,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Short-term Pain Management/Maximum Pain Score,EPREOP4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Review of Functional Status Assessment for Patients with Osteoarthritis,FORCE20,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Review of Pain Status Assessment for Patients with Osteoarthritis,FORCE21,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improvement in Pain after Knee Replacement,FORCE22,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Improvement in Pain after Hip Replacement,FORCE23,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate management of anticoagulation in the peri-procedural period rate � EGD,GIQIC10,Registry/QCDR,Process,Y,31.25 - 52.34,52.35 - 61.53,61.54 - 66.77,66.78 - 81.35,81.36 - 90.90,90.91 - 98.90,98.91 - 99.99,100,No
Appropriate indication for colonoscopy,GIQIC12,Registry/QCDR,Process,Y,83.71 - 87.91,87.92 - 90.17,90.18 - 91.82,91.83 - 93.51,93.52 - 95.00,95.01 - 96.57,96.58 - 98.14,>= 98.15,No
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients,GIQIC15,Registry/QCDR,Process,Y,61.11 - 71.42,71.43 - 76.09,76.10 - 79.19,79.20 - 83.66,83.67 - 87.12,87.13 - 90.23,90.24 - 93.74,>= 93.75,No
Appropriate follow-up interval of 5 years for colonoscopies with findings of sessile serrated polyps < 10 mm without dysplasia,GIQIC17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm,GIQIC18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate indication for esophagogastroduodenoscopy (EGD),GIQIC19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate follow-up interval of 10 years for colonoscopies with only hyperplastic polyp findings,GIQIC20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HAdv1 - Use of high risk sleep medications in the elderly,HADV1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HAdv2 - Atrial Fibrillation Prevention and Treatment � Lifestyle and Disease Factor Assessment,HADV2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Mean Length of Stay for Inpatients � Pneumonia,HCPR3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Length of Stay for Inpatients � CHF,HCPR4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Mean Length of Stay for Inpatients � COPD,HCPR5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Stroke Venous Thromboembolism (VTE) Prophylaxis,HCPR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Venous Thromboembolism (VTE) Prophylaxis,HCPR14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Physician�s Orders for Life-Sustaining Treatment (POLST) Form,HCPR16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pressure Ulcers - Risk Assessment and Plan of Care,HCPR17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unintentional Weight Loss - Risk Assessment and Plan of Care,HCPR18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
30 Day All-Cause Readmission Rate for Discharged Inpatients,HCPR19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Clostridium Difficile - Risk Assessment and Plan of Care,HCPR20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Use of Telemetry for Admission or Observation Placement ,HCPR21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Care Transfer of Care - Use of Verbal Checklist or Protocol,HCPR22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Exclusive Breast Milk Feeding,HEF1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Surgical Reconstruction for Anterior Cruciate Ligament (ACL) Injury,HF2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Shoulder Instability - Labral Reconstruction: Change in Validated Shoulder Patient Reported Outcome Measure Following Labral Reconstruction for Shoulder,HF3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Shoulder Arthroscopy: Measure of Change in a Validated Shoulder Patient Reported Outcome Following Shoulder Arthroscopy,HF4,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Shoulder Arthroplasty: Change in a Validated Shoulder Patient Reported Outcome Measure Following Shoulder Arthroplasty,HF5,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Knee Arthroscopy for Meniscal Repair: Change in a Validated Knee Patient Reported Outcome Measure Following Knee Arthroscopy for Meniscal Repair,HF6,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Repair for Rotator Cuff Tear: Change in a Validated Shoulder Patient Reported Outcome Measure Following Surgical Rotator Cuff Repair,HF7,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
ACE/ARB use,HM1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A1C treatment ,HM2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A1C in good control,HM3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Hypogonadism: Serum T, CBC, PSA, IPSS within 6  months of Rx",IQSS1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Prostate Cancer: Newly diagnosed with document T, PSA, Gleason and Prostate Cancer: Initial Eval. Document T, PSA, Gleason",IQSS2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Treatment Options Counseling,IQSS3,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
BPH: Anticholinergics,IQSS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Counseling SUI,IQSS5,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Endothelial Keratoplasty: Post-operative improvement in best corrected visual acuity to 20/40 or greater,IRIS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Exudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Nonexudative Age-Related Macular Degeneration - Loss of Visual Acuity ,IRIS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acute Anterior Uveitis - Post-treatment visual acuity,IRIS16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acute Anterior Uveitis - Post-treatment Grade 0 anterior chamber cells,IRIS17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Chronic Anterior Uveitis -  Post-treatment visual acuity,IRIS18,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma -  Intraocular Pressure (IOP) Reduction,IRIS2,Registry/QCDR,Outcome,Y,86.96 - 97.36,97.37 - 98.99,99.00 - 99.99,--,--,--,--,100,Yes
Idiopathic Intracranial Hypertension:  No worsening or improvement of mean deviation,IRIS20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Ocular Myasthenia Gravis:  Improvement of ocular deviation or absence of diplopia or functional improvement,IRIS21,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Giant Cell Arteritis:  Absence of fellow eye involvement after treatment ,IRIS22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Refractive Surgery: Postoperative Improvement in Uncorrected Visual Acuity of 20/20 or better ,IRIS23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Refractive Surgery:  Postoperative correction within + 0.5 Diopter of the Intended Correction,IRIS24,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Adenoviral Conjunctivitis:  Avoidance of Antibiotics,IRIS25,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Intravitreal Injections: Avoidance of Routine Antibiotic Use,IRIS26,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Adverse Events After Cataract Surgery,IRIS27,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Regaining Vision After Cataract Surgery,IRIS28,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Improved visual acuity after epiretinal membrane treatment within 90 days,IRIS29,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Visual Field Progression,IRIS3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Return to OR within 90 days after epiretinal membrane surgical treatment,IRIS30,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Avoidance of Genetic Testing for Age-related Macular Degeneration,IRIS31,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Evidence of anatomic closure of macular hole within 90 days after surgery as documented by OCT.,IRIS32,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Return to OR within 90 days after macular hole surgery,IRIS33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Age-Related Macular Degeneration: Disease Progression,IRIS34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Glaucoma - Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgery for Acquired Involutional Ptosis - Patients with an Improvement of Marginal Reflex Distance,IRIS5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Acquired Involutional Entropion -  Normalized Lid Position After Surgical Repair,IRIS6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Amblyopia - Interocular Visual Acuity,IRIS7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Surgical Esotropia - Postoperative Alignment,IRIS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Diabetic Retinopathy - Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy,IRIS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Functional Improvement in hip, leg or ankle rehabilitation in patients with lower extremity injury measured via the validated Lower Extremity Function Scale (LEFS) score. ",IROMS1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Improvement in low back rehabilitation of non-surgical patients with low pack pain measured via the validated Modified Low Back Pain Disability Questionnaire (MDQ).,IROMS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Improvement in knee rehabilitation of patients with knee injury measured via their validated Knee Outcome Survey (KOS) score.,IROMS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Functional Improvement in arm, shoulder, and hand rehabilitation in surgical patients with musculotendinous injury measured via the validated Disability of Arm Shoulder and Hand (DASH) score.",IROMS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Improvement in neck pain/injury patients rehabilitation measured via the validated Neck Disability Index (NDI).,IROMS9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 1: Procedures with statin and antiplatelet agents prescribed at discharge,M2S1,Registry/QCDR,Process,Y,70.25 - 77.54,77.55 - 80.46,80.47 - 81.25,81.26 - 81.61,81.62 - 84.56,84.57 - 89.82,89.83 - 92.81,>= 92.82,No
M2S 10: Survival at least 9 months after elective repair of small thoracic aortic aneurysms ,M2S10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 11: Imaging-based maximum aortic diameter assessed at least 9 months following Endovascular AAA Repair procedures,M2S11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"M2S 12: Survival at least 9 months after elective repair Endovascular AAA Repair of small abdominal aortic aneurysms
",M2S12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"M2S 13: Survival at least 9 months after elective Open AAA repair of small abdominal aortic aneurysms

",M2S13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Absence of unplanned reoperation after closed lower extremity major amputation,M2S16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 17: Absence of serious technical complications during peripheral arterial intervention,M2S17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 19: Proper patient selection for perforator vein ablation,M2S19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"M2S 2: Amputation-free survival assessed at least 9 months following Infra-Inguinal Bypass for intermittent claudication

",M2S2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 5: Amputation-free survival at assessed at least 9 months following Peripheral Vascular Intervention for intermittent claudication,M2S5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"M2S 7: Ipsilateral stroke-free survival at assessed at least 9 months following Carotid Artery Stenting for asymptomatic procedures 

",M2S7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
" M2S 8: Ipsilateral stroke-free survival assessed at least 9 months following isolated Carotid Endarterectomy for asymptomatic procedures 

",M2S8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
M2S 9: Imaging-based maximum aortic diameter assessed at least 9 months following Thoracic and Complex EVAR procedures,M2S9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Case Delay,MA1,Registry/QCDR,Efficiency,N,--,--,--,--,--,--,--,--,--
Corneal Abrasion,MA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Anxiety Utilization of the GAD-7 Tool,MBHR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Anxiety Response at 6-months,MBHR2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Risk standardized rate of patients who experienced a postoperative escalation in care event following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP10,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Risk standardized rate of patients who experienced a pulmonary complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy,MBSAQIP11,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
Risk standardized rate of patients who experienced a postoperative complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP12,Registry/QCDR,Composite,N,--,--,--,--,--,--,--,--,--
"Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation",MBSAQIP7,Registry/QCDR,Outcome,Y,2.13 - 1.85,1.84 - 1.29,1.28 - 0.40,0.39 - 0.01,--,--,--,0,Yes
Risk standardized rate of patients who experienced an extended length of stay (> 3 days) following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP8,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0,Yes
Use of a �PEG Test� to Manage Patients Receiving Opioids,MEDNAX52,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX1: Heel Pain Treatment Outcomes for Adults,MEX1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Vascular Testing Outcome Measure Supervised Programs,MEX10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-19: Non-Invasive Vascular Testing in Patients with Abnormal CVI Screening That Completed Hyperbaric Oxygen Therapy ,MEX11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peripheral Vascular Assessment % of Diabetic Patients 50+ ,MEX12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX2018-22: Patients with Lower Limb Ulceration with a Previously Abnormal Vascular Study Receiving Negative Pressure Wound Therapy ,MEX13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2: Heel Pain Treatment Outcomes for Pediatric Patients,MEX2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX3: Identification of Flat Foot in Pediatric Patients,MEX3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX2018-2: Bunion Outcome - Adult and Adolescent,MEX4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-3: Hammer Toe Outcome,MEX5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-11: Peripheral Vascular Assessment - Patients 70+,MEX6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
MEX2018-6: Foot Wound Outcome,MEX7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-20: Non-Invasive Vascular Testing Follow-up in Patients After Revascularization,MEX8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
MEX2018-16: Non-Invasive Vascular Testing in Patients Diagnosed with Intermittent Claudication Who Use Cilostazol or Pentoxifylline,MEX9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Plan All Cause Readmissions,MHAN3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
General Health Postoperative Improvement,MICS1,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Surgery Specific Postoperative Improvement in Pain Levels,MICS2,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Surgery Specific Postoperative Improvement in Function Levels,MICS3,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Perioperative Pain Plan,MIRAMED16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of witnessed gastric aspiration,MIRAMED17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Conversion to General Anesthesia from Regional or MAC for all scheduled cases,MIRAMED18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Onset atrial fibrillation or dysrthymia requiring unanticipated therapy,MIRAMED19,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Perioperative cognitive function test in elderly,MIRAMED20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Ischemic Vascular Disease Use of Aspirin or Anti-platelet Medication,MNCM5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes A1c Control (<8.0),MNCM6,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
Objectifying pain and/or functionality to determine manipulative medicine efficacy with correlative treatment adjustment,MOA1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Treatment of spinal stenosis with manipulative medicine and alternative medicine modalities,MOA12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Urine Drug Screen Utilization in Pain Management and Substance Use Disorders; no less than quarterly for pain and no less than monthly for substance use disorders,MOA13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Addressing anxiety in pain patients with SNRI and SSRIs and reducing/eliminating benzodiazepines for chronic anxiety,MOA14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Weight loss in pain patients with BMI > = 30 with opiate utilization for weight related pain conditions rather than opiate dose escalation for improved pain control,MOA15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Appropriate use of advanced imaging by ordering provider with glucocorticoid management to spare motor neuron loss when physical findings suggest neuropathic etiology,MOA2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate controlled substance prescribing (definitive diagnosis(es)) via adherence to Controlled Substance Agreements (CSA) or (OA's) with corrective action taken for pain and/or substance use disorder patients when violations occur,MOA7,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Pre-surgical screening for depression,MSSIC1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for pain-related disability (ODI/NDI),MSSIC10,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Percent Satisfied with Result,MSSIC11,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of hospital readmission,MSSIC12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of surgical site infection,MSSIC13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted rate of urinary retention,MSSIC14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for myelopathy,MSSIC16,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Percent same-day ambulation,MSSIC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of use of Pre-op skin preparation/wash,MSSIC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for back or neck pain,MSSIC8,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients achieving MCID for leg or arm pain,MSSIC9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy Antibiotic Compliance,MUSIC1,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100,Yes
Prostate Cancer: Confirmation Testing in low risk AS eligible patients,MUSIC10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months,MUSIC11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients,MUSIC3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer: Active Surveillance/Watchful Waiting for Low Risk Prostate Cancer Patients,MUSIC4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prostate Cancer:  Radical Prostatectomy Cases LOS,MUSIC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prostate Biopsy: Repeat Biopsy for Patients with Atypical Small Acinar Proliferation (ASAP),MUSIC9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Telephone Contact, Virtual, or In-person Visit Within 48 Hours of Hospital Discharge of Home-Based Primary Care and Palliative Care Patients",NHBPC10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Interdisciplinary Team Assessment for Home-Based Primary care and Palliative Care Patients,NHBPC13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cognitive Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
A Functional Assessment (Basic and Instrumental Activities of Daily Living [ADL]) for Home-Based Primary Care and Palliative Care Patients (Multiperformance Measure),NHBPC15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Outcome for Home-Based Primary Care and Palliative Care Practices   ,NHBPC16,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Screening for Depression and Follow-up Plan in Home-Based Primary Care and Palliative Care Patients,NHBPC17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Alcohol Problem Use Assessment for Home-Based Primary Care and Palliative Care Patients,NHBPC2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screen for Risk of Future Fall for Home-Based Primary Care and Palliative Care Patients,NHBPC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Delirium Assessment in Home-Based Primary Care and Palliative Care Patients: Medication List Reviewed & Offending Medications Discontinued (Multiperformance-Rate Measure),NHBPC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Referral to Hospice for Appropriate Home-Based Primary Care and Palliative Care Patients,NHBPC9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
NHCR4: Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation ,NHCR4,Registry/QCDR,Process,Y,12.50 - 19.37,19.38 - 23.66,23.67 - 33.98,33.99 - 40.33,40.34 - 49.38,49.39 - 68.20,68.21 - 80.29,>= 80.30,No
NHCR5: Repeat colonoscopy recommended due to piecemeal resection,NHCR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate indication for colonoscopy,NHCR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
COMMUNICATING CONCURRENT OPIOID AND BENZODIAZEPINE PRESCRIBING TO OTHER PRESCRIBERS,NIPM10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
PATIENT COUNSELING REGARDING RISKS OF CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES,NIPM11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
FUNCTIONAL STATUS ASSESSMENT FOR SPINAL CORD STIMULATOR IMPLANTATION,NIPM12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
FUNCTIONAL STATUS ASSESSMENT FOR LUMBAR MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM13,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
FUNCTIONAL STATUS ASSESSMENT FOR CERVICAL MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
REDUCTION IN PATIENT REPORTED PAIN FOLLOWING SPINAL CORD STIMULATOR IMPLANTATION FOR FAILED BACK SURGERY SYNDROME,NIPM15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
REDUCTION IN PATIENT REPORTED PAIN FOLLOWING LUMBAR MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
REDUCTION IN PATIENT REPORTED PAIN FOLLOWING CERVICAL/THORACIC MEDIAL BRANCH RADIOFREQUENCY ABLATION,NIPM17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
APPROPRIATE PATIENT SELECTION FOR DIAGNOSTIC FACET JOINT PROCEDURES,NIPM4,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
AVOIDING EXCESSIVE USE OF EPIDURAL INJECTIONS IN MANAGING CHRONIC PAIN ORIGINATING IN THE CERVICAL AND THORACIC SPINE,NIPM8,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
AVOIDING EXCESSIVE USE OF THERAPEUTIC FACET JOINT INTERVENTIONS IN MANAGING CHRONIC CERVICAL AND THORACIC SPINAL PAIN ,NIPM9,Registry/QCDR,Cost/Resource Use,N,--,--,--,--,--,--,--,--,--
Critical Result: Pulmonary Embolism,NJIISMD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Ruptured Ectopic Pregnancy,NJIISMD10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: New Deep Venous Thrombosis (DVT),NJIISMD11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Ectopic Pregnancy,NJIISMD12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Result Requiring Follow Up Protocol,NJIISMD17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Cord Compression,NJIISMD19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: ICH,NJIISMD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: CTA of GI bleed,NJIISMD20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Positive bleeding scan,NJIISMD21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Acute Ocular injury,NJIISMD22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Aortic Dissection,NJIISMD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Occlusive Intracranial Stroke,NJIISMD8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result: Placental abruption,NJIISMD9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Substance Use Screening,NNEPTN1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: Substance Use Screening and Intervention Composite,NNEPTN2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transforming Clinical Practice Initiative Common Measure Name: TCP01: Documentation of a Comprehensive Health and Life Plan Developed Collaboratively by the Patient and the Health Professional Team,NNEPTN3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Median Time to Pain Management for Long Bone Fracture,NOF12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older",NOF13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hip Fracture Mortality Rate (IQI 19),NOF6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Osteoporosis: percentage of patients, any age, with a diagnosis of osteoporosis who are either receiving both calcium & vitamin D intake, & exercise at least once within 12 months.",NOF7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unplanned Readmission Following Spine Procedure within the 30-Day Postoperative Period,NPA11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Selection of Prophylactic Antibiotic Prior to Spine Procedure,NPA12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medicine Reconciliation Following Spine Related Procedure,NPA14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Risk Assessment for Elective Spine Procedure,NPA15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Depression and Anxiety Assessment Prior to Spine-Related Therapies,NPA16,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Narcotic Pain Medicine Management Following Elective Spine Procedure,NPA17,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Smoking Assessment and Cessation Coincident With Spine-Related Therapies,NPA18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Body Mass Assessment and Follow-up Coincident With Spine-Related Therapies,NPA19,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Unhealthy Alcohol Use Assessment Coincident With Spine Care,NPA20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Spine/Extremity Pain Assessment,NPA23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Outcome Assessment for Spine Intervention,NPA3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality-of-Life Assessment for Spine Intervention,NPA4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction With Spine Care,NPA5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Spine-Related Procedure Site Infection,NPA6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Spine/Extremity Pain Assessment ,NPAGSC10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Outcome Assessment for Spine Intervention ,NPAGSC3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Quality-of-Life Assessment for Spine Intervention ,NPAGSC4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Satisfaction with Spine Care ,NPAGSC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Depression and Anxiety Assessment Prior to Spine-Related Therapies,NPAGSC6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Narcotic Pain Medicine Management Prior to and Following Spine Therapy ,NPAGSC7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Complication Following Percutaneous Spine-Related Procedure ,NPAGSC8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Unplanned Admission to Hospital Following Percutaneous Spine Procedure within the 30-Day Post-procedure Period ,NPAGSC9,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Notification to the ordering provider requesting myoglobin or CK-MB in the diagnosis of suspected acute myocardial infarction (AMI). ,NPQR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of amended pathology reports with a major discrepancy,NPQR10,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of communicating results of an amended report with a major discrepancy to the responsible provider ,NPQR11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of cytopathology case review,NPQR12,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of notification to clinical provider of a new diagnosis of malignancy ,NPQR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Frozen section diagnosis within 20 minutes of receipt in lab (single block frozen section),NPQR14,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Notification to the ordering provider requesting thyroid screening tests other than only a Thyroid Stimulating Hormone (TSH) test in the initial screening of a patient with a suspected thyroid disorder,NPQR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Notification to the ordering provider requesting amylase testing in the diagnosis of suspected acute pancreatitis,NPQR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for chemistry,NPQR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for cerebrospinal fluid - white blood cell (CSF - WBC),NPQR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for toxicology,NPQR6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Time interval: critical value reporting for troponin,NPQR7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of review of slides with high-grade squamous intraepithelial lesion (HSIL) with negative cervical biopsies,NPQR8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Rate of follow up letter after high-grade squamous intraepithelial lesion (HSIL) pap test,NPQR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post Stroke Outcome and Follow-Up,OBERD22,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Health Related Quality of Life: Patient Defined Outcomes,OBERD23,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Tracking Satisfaction Improvement with CG-CAHPS,OBERD25,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Cervical Spine Functional Outcomes,OBERD26,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Foot/Ankle Functional Outcomes,OBERD27,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Hip Functional Outcomes,OBERD28,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Knee Functional Outcomes,OBERD29,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Lumbar Spine Functional Outcomes,OBERD30,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life-Mental Health Outcomes,OBERD31,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Quality of Life - Physical Health Outcomes,OBERD32,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Patient Acceptable Symptom State Outcomes,OBERD33,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Upper Extremity Functional Outcomes,OBERD34,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"Emergent transfer from an outpatient, ambulatory surgical center, or office setting",OEIS2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Antiplatelet Therapy,OEIS3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Lipid-Lowering Medications for Patients with PAD,OEIS4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
 Appropriate non-invasive arterial testing for patients with intermittent claudication who are undergoing a LE peripheral vascular intervention,OEIS6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Goal Setting and Attainment for Cancer Survivors,ONSQIR18,Registry/QCDR,Patient Engagement Experience,N,--,--,--,--,--,--,--,--,--
Fatigue Improvement,ONSQIR20,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Advance Care Planning in Stage 4 Disease,PIMSH1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Utilization of GCSF in Metastatic Colon Cancer,PIMSH2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0 or Stage IB-III hormone receptor negative breast cancer,PIMSH3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Risk-adjusted 30 day Readmission for Acute Myocardial Infarction,PINC1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted 30 day Readmission for Heart Failure,PINC2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted 30 day Readmission for Pneumonia,PINC3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Acute Myocardial Infarction,PINC33,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Heart Failure,PINC34,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-Adjusted Average Length of Inpatient Hospital Stay for Pneumonia,PINC35,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted 30 day Inpatient Mortality for Acute Myocardial Infarction,PINC4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted 30 day Inpatient Mortality for Heart Failure ,PINC5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risk-adjusted 30 day Inpatient Mortality for Pneumonia,PINC6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Annual Monitoring for Patients on Persistent Medications (MPM),PP1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Follow-Up After Hospitalization for Schizophrenia (7- and 30-day),PP2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ADHD: Symptom Reduction in Follow up Period,PP3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Risky Behavior Assessment or Counseling by Age 18 Years,PP4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Bipolar disorder: the percentage of patients diagnosed and treated for bipolar disorder who are monitored for change in their symptom complex within 12 weeks of initiating treatment; AND if there is no change or deterioration in symptoms, a revised care plan is documented following the 12 week monitoring phase",PP5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Pharmacological Treatment of Dementia,PP6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC),PP7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Chronic Kidney Disease (CKD): eGFR Monitoring,PPRNET13,Registry/QCDR,Process,Y,62.50 - 64.85,64.86 - 70.58,70.59 - 73.32,73.33 - 76.04,76.05 - 80.18,80.19 - 84.23,84.24 - 89.05,>= 89.06,No
Chronic Kidney Disease (CKD): Hemoglobin Monitoring,PPRNET14,Registry/QCDR,Process,Y,72.62 - 77.21,77.22 - 82.85,82.86 - 87.29,87.30 - 89.86,89.87 - 90.53,90.54 - 93.09,93.10 - 94.58,>= 94.59,No
Appropriate Treatment for Adults with Upper Respiratory Infection,PPRNET24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"NSAID or Cox 2 Inhibitor Use in Patients with Heart Failure (HF), Hypertension (HTN), or Chronic Kidney Disease (CKD)",PPRNET28,Registry/QCDR,Process,Y,80.00 - 81.80,81.81 - 82.91,82.92 - 84.83,84.84 - 85.94,85.95 - 86.76,86.77 - 91.40,91.41 - 93.07,>= 93.08,No
Monitoring Serum Creatinine,PPRNET29,Registry/QCDR,Process,Y,73.35 - 78.88,78.89 - 84.40,84.41 - 86.29,86.30 - 88.09,88.10 - 90.88,90.89 - 93.85,93.86 - 96.29,>= 96.30,No
Screening for Type 2 Diabetes,PPRNET31,Registry/QCDR,Process,Y,82.72 - 84.17,84.18 - 85.53,85.54 - 87.24,87.25 - 90.70,90.71 - 92.15,92.16 - 93.92,93.93 - 96.19,>= 96.20,No
Screening for albuminuria in patients at risk for CKD (DM and/or HTN),PPRNET32,Registry/QCDR,Process,Y,18.26 - 26.78,26.79 - 47.26,47.27 - 56.41,56.42 - 61.65,61.66 - 66.11,66.12 - 72.25,72.26 - 75.06,>= 75.07,No
Avoiding Use of CNS Depressants in Patients on Long-Term Opioids,PPRNET33,Registry/QCDR,Process,Y,50.51 - 54.54,54.55 - 55.58,55.59 - 57.79,57.80 - 60.14,60.15 - 65.24,65.25 - 72.38,72.39 - 81.62,>= 81.63,No
Zoster (Shingles) Vaccination,PPRNET34,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Antiplatelet Medication for High Risk Patients,PPRNET8,Registry/QCDR,Process,Y,27.68 - 36.18,36.19 - 41.59,41.60 - 47.90,47.91 - 50.61,50.62 - 59.08,59.09 - 67.67,67.68 - 74.60,>= 74.61,No
Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) to III ER/PR negative breast cancer,QOPI11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
GCSF administered to patients who received chemotherapy for metastatic cancer (Lower Score -Better),QOPI15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Oncology: Treatment Summary Communication � Radiation Oncology,QOPI21,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
External Beam Radiotherapy for Bone Metastases,QOPI22,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented  (Lower Score - Better)",QOPI5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Central Line Ultrasound Guidance,QUANTUM31,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Case Cancellation on Day of Surgery,QUANTUM41,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
CKD 3-5 Patients Seen at the Recommended Frequency Levels,RCOIR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Upper Extremity Edema Improvement,RCOIR10,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Optimal End Stage Renal Disease (ESRD) Starts,RCOIR11,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 3-5 Patients with a Urine ACR or Urine PCR Lab Test,RCOIR3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
CKD 4-5 Patients with Transplant Referral,RCOIR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
ESRD Prevalence of Home Dialysis or Self-Care,RCOIR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Improved Access Site Bleeding,RCOIR7,Registry/QCDR,Outcome,Y,37.04 - 40.21,40.22 - 44.52,44.53 - 59.99,60.00 - 63.63,63.64 - 66.66,66.67 - 69.22,69.23 - 74.99,>= 75.00,No
Post Procedure Bleeding,RCOIR8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy,RPAQIR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Hospitalization Rate Following Procedures Performed under Procedure Sedation Analgesia,RPAQIR11,Registry/QCDR,Outcome,Y,0.58 - 0.27,0.26 - 0.08,0.07 - 0.01,--,--,--,--,0,Yes
Arterial Complication Rate Following Arteriovenous Access Intervention,RPAQIR12,Registry/QCDR,Outcome,Y,0.99 - 0.74,0.73 - 0.55,0.54 - 0.40,0.39 - 0.01,--,--,--,0,Yes
Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician,RPAQIR13,Registry/QCDR,Process,Y,92.85 - 94.06,94.07 - 94.94,94.95 - 95.86,95.87 - 97.27,97.28 - 97.88,97.89 - 99.20,99.21 - 99.76,>= 99.77,Yes
Arteriovenous Graft Thrombectomy Success Rate,RPAQIR14,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Arteriovenous Fistulae Thrombectomy Success Rate,RPAQIR15,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peritoneal Dialysis Catheter Success Rate,RPAQIR16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Peritoneal Dialysis Catheter Exit Site Infection Rate,RPAQIR17,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Advance Directives Completed,RPAQIR18,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Adequacy of Volume Management,RPAQIR2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Arteriovenous Fistula Rate,RPAQIR4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Transplant Referral,RPAQIR5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Advance Care Planning (Pediatric Kidney Disease),RPAQIR9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Improvement in Quality of Life from Partial Foot, Prosthetics ",SCG05,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
SCG1 Evaluation of High Risk Pain Medications for MME,SCG1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SCG2 Outcome Assessment for Patients Prescribed Ankle Orthosis for Ambulation and Functional Improvement,SCG2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Outcome Assessment for Patients Prescribed Foot Orthosis for Ambulation and Functional Improvement ,SCG3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Prevention of Antibiotic or Herbal Supplement Impairment of Anesthesia ,SCG4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Outcome of High Risk Pain Medications Prescribed in Last 6 Months,SCG6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Education of patients with inflammatory diseases regarding increased cardiovascular risk and the need for PCP evaluation,SDPAD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
HCV testing in Lichen Planus,SDPAD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Avoiding antibiotic use in rupture epidermal inclusion cyst,SDPAD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Appropriate Testing and Treatment of Nail tinea infection,SDPAD4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Urgent Result:  Breast Specimen Radiography,SMD23,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result:  Testicular Torsion,SMD24,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Critical Result:  Subdural hematoma,SMD25,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"GI Radiography Result Notification
�Critical Result:  Bowel Obstruction
�Critical Result:  Sigmoid Volvulus",SMD26,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Chest Imaging Result Notification:
�Critical Result:  Pneumothorax
�Critical Result:  Tension Pneumothorax
�Follow Up Result:  Suspicious Lung Nodule",SMD27,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Musculoskeletal Radiology Result Notification:
�Critical Result:  Fracture C-Spine
�Urgent Result: Osteomyelitis
�Urgent Result:  Meniscal Tear
",SMD28,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia,SMX1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications,SMX2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
SMX1004: Use of Multiple Concurrent Antipsychotics in Children and Adolescents,SMX3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Adherence for Diabetes Medication,SMX5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Screening for Psychiatric or Behavioral Health Disorders,SMX6,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Medication Adherence for Hypertension,SMX7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment and Intervention for Psychosocial Distress in Adults Receiving Cancer Treatment ,SMX8,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Mental Health Assessment for Patients with orthopedic conditions,SMX9,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Repeated X-ray Imaging,SPINEIQ3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Change in Functional Outcomes,SPINEIQ5,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Change in Pain Intensity,SPINEIQ6,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
MRI  of the lumbar spine without prior conservative care,SPINEIQ7,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Assessment and Management of Muscle Spasticity--Inpatient,SQOD1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Management of Muscle Spasticity--Outpatient,SQOD2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Post-Acute Brain Injury: Depression Screening and Follow-Up Plan of Care,SQOD3,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Family Training�Inpatient Rehabilitation/Skilled Nursing Facility-Discharged to Home,SQOD4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Functional Assessment to Determine Rehabilitation Needs,SQOD5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prolonged Length of Stay Following Coronary Artery Bypass Grafting,STS1,Registry/QCDR,Outcome,Y,8.26 - 6.97,6.96 - 5.89,5.88 - 4.63,4.62 - 3.50,3.49 - 2.74,2.73 - 1.84,1.83 - 0.01,0,No
Operative Mortality for Lobectomy,STS10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lobectomy � Air Leak Greater than 5 Days,STS11,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Lobectomy � Unplanned Return to OR,STS12,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Recording Performance Status Prior to Lung Cancer Resection,STS13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Prolonged Length of Stay for Coronary Artery Bypass Grafting (CABG) + Valve Replacement,STS3,Registry/QCDR,Outcome,Y,21.21 - 14.30,14.29 - 9.10,9.09 - 7.46,7.45 - 5.01,5.00 - 4.77,4.76 - 2.71,2.70 - 0.01,0,Yes
Prolonged Length of Stay following Valve Surgery,STS5,Registry/QCDR,Outcome,Y,8.00 - 5.89,5.88 - 5.27,5.26 - 4.09,4.08 - 3.46,3.45 - 3.04,3.03 - 1.62,1.61 - 0.01,0,No
Patient Centered Surgical Risk Assessment and Communication for Cardiac Surgery ,STS7,Registry/QCDR,Patient Engagement Experience,Y,2.73 - 6.55,6.56 - 22.77,22.78 - 51.51,51.52 - 69.99,70.00 - 83.77,83.78 - 92.47,92.48 - 99.16,>= 99.17,No
Operative Mortality for Esophageal Resection,STS8,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Recording Performance Status prior to Esophageal Cancer Resection,STS9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting MCID thresholds for back or neck pain,SPINETRACK1,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting MCID thresholds for leg or arm pain,SPINETRACK2,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Percent of patients meeting MCID thresholds for pain-related disability (ODI/NDI)
",SPINETRACK3,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
"Percent of patients meeting SCB thresholds for back or neck pain
",SPINETRACK4,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting SCB thresholds for leg or arm pain,SPINETRACK5,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Percent of patients meeting SCB thresholds for pain-related disability (ODI/NDI),SPINETRACK6,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
UR002 - Ankylosing Spondylitis: Controlled Disease,UREQA1,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
UR003 - Ankylosing Spondylitis: Appropriate Pharmacologic Therapy,UREQA2,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
UR008 - Controlled Gout for Patients on Urate-Lowering Pharmacologic Therapy ,UREQA3,Registry/QCDR,Intermediate Outcome,N,--,--,--,--,--,--,--,--,--
UR007 - Folic or Folinic Acid Therapy for Patients Treated with Methotrexate,UREQA4,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
UR006 - Regular Evaluation of Psoriatic Arthritis (PsA),UREQA5,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Vital Sign Assessment and Blood Glucose Check Prior to HBOT Treatment,USWR13,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
"Major Amputation in Wagner 3, 4, or 5 Diabetic Foot Ulcers (DFUs) Treated with HBOT
",USWR16,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Nutritional Screening and Intervention Plan in Patients with Chronic Wounds and Ulcers,USWR20,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Patient Reported Nutritional Assessment in Patients with Wounds and Ulcers,USWR22,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential ,USWR23,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Patient Reported Experience of Care: Wound Outcome,USWR24,Registry/QCDR,Patient Reported Outcome,N,--,--,--,--,--,--,--,--,--
"Advance Care planning: Electronic submission of new POLST/MOLST/POST/MOST (""orders for life-sustaining treatment"" or ""orders for scope of treatment"") into an eRegistry powered by Medcordance",VCMAHEMR1,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Care All or None Outcome Measure: Optimal Control ,WCHQ10,Registry/QCDR,Outcome,N,--,--,--,--,--,--,--,--,--
Screening For Osteoporosis ,WCHQ15,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Controlling High Blood Pressure: eGFR Test Annually,WCHQ32,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--
Diabetes Care All or None Process Measure: Optimal Testing,WCHQ9,Registry/QCDR,Process,N,--,--,--,--,--,--,--,--,--